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ABSTRACT 
Atherosclerotic cardiovascular disease (ASCVD) is the leading worldwide cause of mortality 
and morbidity, being both an economic burden for healthcare systems and a source of great 
individual suffering. The low density lipoprotein cholesterol (LDL-C) concentration in plasma 
is a causal and modifiable risk factor for ASCVD. 
Atherogenesis is initiated and then driven by retention, modification, and aggregation of low 
density lipoprotein (LDL) particles in the arterial intima. Experimental work by our group and 
others has demonstrated that aggregated LDL particles can induce lipid accumulation in 
macrophages and this can also activate intimal cells and thereby induce inflammation in the 
arterial wall. Here, it was hypothesized that it is not only the plasma concentration of LDL 
particles that influences atherogenesis, but also their characteristics. This thesis aims at testing 
whether subjects with aggregation-prone LDL have an increased risk for ASCVD and/or 
ASCVD death. For this purpose, a method to measure LDL aggregation susceptibility was 
developed, and it was further studied if LDL aggregation susceptibility is modifiable. In 
addition, it is studied here if LDL aggregates cause a heightened inflammatory response in 
cells present in the artery wall.  
The first publication was a hypothesis-generating study, where it was discovered that LDL 
particles from ASCVD patients are more prone to aggregate in comparison to those from 
healthy individuals, and importantly, that aggregation-prone LDL predicted future ASCVD 
death in a group of patients with established ASCVD. It was found that the aggregation-prone 
LDL particles are rich in sphingolipids but have less phosphatidylcholines than their 
aggregation-resistant LDL counterparts. Three interventions in animal models aimed at 
altering the LDL composition, were observed not only to lower the susceptibility LDL 
particles to aggregate but also to slow the development of atherosclerosis. Similar 
compositional changes induced in humans by proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibition or adoption of a healthy Nordic diet also lowered the LDL aggregation 
susceptibility.   
In the second publication it was demonstrated that genetic background, here ethnicity, 
influenced LDL aggregation susceptibility. LDL particles from South Asians were more 
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prone to aggregate compared to those from white Caucasians, a finding that may partly 
explain why South Asians are at higher risk for ASCVD. 
The third study was a dietary intervention to investigate if different macronutrients could 
alter LDL particles aggregation susceptibility. Saturated fats were found to increase LDL 
aggregation, while unsaturated fats or simple sugars had no effect.  
In addition, the consumption of plant stanol esters, that are known to reduce the LDL-C 
concentration, was found to decrease the LDL aggregation susceptibility. 
This thesis propose that the aggregation susceptibility of LDL particles is a novel modifiable 
risk factor of ASCVD; its assessment may add predictive power to the conventional ASCVD 
risk estimation. The evaluation of this biomarker may facilitate the identification of those 
patients who would benefit most from aggressive LDL-C-lowering therapies.  
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TIIVISTELMÄ 
Ateroskleroosi eli valtimonkovettumatauti on maailman yleisin kuolinsyy ja se kehittyy 
vuosien kuluessa lapsuudesta lähtien. Plasman LDL-hiukkasten kolesterolipitoisuus on 
merkittävä riskitekijä taudin kehittymiselle, mikä on näytetty geneettisissä, epidemiologisissa 
ja kliinisissä tutkimuksissa.  
LDL-hiukkasten pitoisuus valtimon seinämän sisäkerroksessa, intimassa, on sama kuin 
plasmassa. LDL-hiukkasten kertyminen valtimon seinämään alkaa plasman LDL kolesteroli 
pitoisuuden ollessa suurempi kuin fysiologinen LDL kolesteroli pitoisuus (1-1,5 mmol/l). 
Intimassa LDL-hiukkaset takertuvat solunulkoiseen tukiverkkoon ja ovat alttiita 
entsymaattisille ja hapettaville muutoksille. Muuntuneet LDL-hiukkaset ovat alttiita 
aggregoitumaan eli takertumaan toisiinsa, ja aggregoituneet LDL-hiukkaset puolestaan 
tarttuvat entistä tiukemmin soluväliaineeseen. LDL-hiukkasten kerääntyminen intimaan 
houkuttelee paikalle makrofageja, jotka fagosytosoivat erityisesti aggregoituneita hiukkasia, 
mikä johtaa vaahtosolujen muodostumiseen ja paikalliseen tulehdukseen. Valtimoplakkien 
tiedetään sisältävän aggregoituneita LDL-hiukkasia ja eläinkokeissa on näytetty, että plasman 
LDL aggregoituu valtimon seinämässä vain kahden tunnin kuluessa siitä, kun eläimeen 
injektoidaan LDL-hiukkasia ja plasman LDL-kolesterolipitoisuus kohoaa. 
Tässä väitöskirjatyössä kehitin menetelmän mitata LDL-hiukkasten aggregoitumisherkkyyttä 
verinäytteistä. Osoitin, että LDL-hiukkasten herkkyys aggregoitua vaihtelee ihmisten välillä 
ja johtuu eroista LDL-hiukkasten pinnan rasvojen suhteista, fosfatidyylikoliinien ja 
sfingomyeliinien suhteellisesta osuudesta. Sfingomyeliiniä paljon sisältävät LDL-hiukkaset 
aggregoituvat herkemmin, ja fosfatidyylikoliinia paljon sisältävät LDL-hiukkaset hitaammin. 
Osoitin, että LDL-hiukkaset aggregoituvat herkemmin sepelvaltimotautipotilailla kuin 
terveillä verrokeilla ja mikä tärkeintä, LDL- hiukkasten aggregoitumisherkkyys ennusti 
tulevaa sydänkuolemaa sepelvaltimotautia sairastavilla potilailla. LDL-hiukkasten 
aggregoitumisherkkyys osoittautui itsenäiseksi riskitekijäksi, eikä korreloinut esimerkiksi 
plasman LDL-kolesterolipitoisuuden tai iän kanssa, eikä eronnut miesten ja naisten välillä. 
Lisäksi osoitin, että LDL-hiukkasten herkkyys aggregoitua riippuu mahdollisesti ainakin 
osittain geneettisistä tekijöistä, sillä eteläaasialaisten LDL aggregoitui herkemmin kuin 
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länsimaalaisten.  
Kliinisesti on tärkeää tietää voiko LDL-hiukkasten aggregoitumisherkkyyteen vaikuttaa 
elintavoilla tai lääkityksellä. Näytin tässä työssä, että ravinnon rasvoilla on merkitystä, sillä 
tyydyttyneet rasvat huononsivat LDL-hiukkasten laatua ja lisäsivät LDL-hiukkasten 
aggregoitumisherkkyyttä.  
Pohjoismainen terveellinen ruokavalio, erityisesti siihen kuuluvat kasviöljyt paransivat LDL-
hiukkasten laatua ja vähensivät aggregoitumista. PCSK9 (proprotein convertase 
subtilisin/kexin 9) estäjä, plasman kolesterolipitoisuutta laskeva monoklonaalinen vasta-
ainelääke vähensi LDL-hiukkasten aggregoitumista parantamalla LDL-hiukkasten laatua.  
Lisäksi havaittiin, että kasviöljypohjaisen kasvistanolia sisältävän levitteen käyttö puolestaan 
paransi LDL-hiukkasten laatua ja vähensi LDL-hiukkasten aggregoitumisherkkyyttä. 
 
Tämä väitöskirjatyö esittelee LDL-hiukkasten aggregoitumisherkkyyden uutena 
muokattavissa olevana riskitekijänä ateroskleroottisille valtimosairauksille. LDL-
hiukkasten aggregoitumisherkkyys voi tulevaisuudessa auttaa tunnistamaan potilaat, jotka 
hyötyisivät eniten aggressivisesta LDL kolesterolia alentavasta lääkityksestä. 
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1 INTRODUCTION 
 
Cardiovascular diseases (CVDs) are the most common global cause of death and this is also 
the case in Finland (1). CVDs caused an estimated 17.6 million deaths in 2016, which 
represents 32% of all global deaths, and 70% of these deaths are due to events related with 
atherosclerotic disease such as heart attack and stroke. CVDs can be prevented to some 
extent by managing behavioural risk factors; of these, the most important detrimental factors 
are unhealthy diet, physical inactivity, smoking and excess use of alcohol (2). These 
behavioural risk factors are associated with physical outcomes such as increased blood 
lipids, elevated blood pressure, high blood glucose, and overweight/obesity. These risk 
factors can be measured in primary care to evaluate the need for lifestyle changes and/or 
medication.  
The low density lipoprotein cholesterol (LDL-C) concentration in plasma is a well-
established independent risk factor of atherosclerotic cardiovascular diseases (ASCVD)s and 
the cause of the disease (3,4). Current guidelines indicate that total cholesterol should be 
under 5 mmol/l and LDL-C under 3 mmol/l. For high risk patients, for example if 
atherosclerosis has been diagnosed, the target level for LDL-C is under 1.4 mmol/l (3).  
ASCVD is initiated and further driven by the retention, modification, and aggregation of low 
density lipoprotein (LDL) particles in the arterial intima. Experimental work has demonstrated 
that aggregated LDL particles can induce lipid accumulation in macrophages and activate 
intimal cells and thereby induce inflammation in the arterial wall (5,6). Therefore in this thesis, 
I hypothesize that it is not only the plasma concentration of LDL-C that influences 
atherogenesis, but also the characteristics of LDL particles. This thesis aims at testing whether 
subjects with aggregation-prone LDL have an increased risk of developing coronary artery 
disease (CAD) and/or CAD deaths, and further if LDL the aggregation susceptibility is 
modifiable. 
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2 REVIEW OF THE LITERATURE 
2.1 ATHEROSCLEROSIS 
CVDs are the leading cause of death and disability around the world and also still in Finland 
despite intensive efforts at prevention and treatment of risk factors (1). Ischemic heart 
disease or CAD, carotid artery disease or cerebrovascular disease, peripheral artery disease 
(PAD) and chronic kidney disease are all classified as CVDs. ASCVD is a CVD that is 
specified as having been caused by atherosclerosis. 
Sudden cardiac death is the cause of every second CAD death. Since most patients are never 
identified as high-risk patients prior to the event, it is evident that the prevention of these 
kinds of deaths is difficult (7-9). Most of the sudden cardiac deaths occur because of CAD, 
of which one third had not been diagnosed (7,8,10-12). The prevention of atherosclerosis 
focuses on the treatment of risk factors, but it seems probable that current treatment goals 
are not stringent enough, and/or that there are still unrecognised risk factors.   
2.1.1 History 
Leonardo Da Vinci was the first to describe an `old man` with the following words ”In the 
proportion as the vessels become old their branches lose their straightness and become so 
much the more bent or tortuous, and their coats thicker, as old age becomes full of years”. 
Around 1506, he also wrote that this `old man` died because of “failure of the artery that 
feeds the heart and lower members” (13,14).  
Atherosclerosis is commonly assumed to be a modern disease, but atherosclerotic lesions 
have been detected already from members of pre-industrial populations including pre-
agricultural hunter-gatherers who died 4000 years ago by studying their mummified remains 
(15). However, this still does not mean that atherosclerosis is normal or an inevitable part of 
human aging.  
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2.1.2 Definitions 
Atherosclerosis is a disease of the arteries where the lumen of the artery narrows due to the 
formation of plaques, causing abnormal blood flow. Atherosclerosis starts to develop in 
childhood and its development usually continues for decades before it evokes any clinical 
symptoms (16-20).  
In childhood, fatty streaks are the first visible sign of atherosclerosis, and they develop into 
intermediate lesions during adolescence and young adulthood (16-18). In an autopsy study, 
early stage aortic atheromas were found from all subjects examined at the age 15-19 years 
(n= 614) and over 50% had coronary lesions (19). Fibroatheromas and calcified lesions 
develop later in adulthood i.e. before the age of 50 years, 80% of men and 47% of women 
have calcified plaques in at least one artery (carotid, coronary, proximal, distal aorta or iliac 
vessels), and at 70 years of age, calcified plaques are ubiquitous in both men and women 
(n=650) (20). 
The symptoms depend on the stage of the atherosclerotic disease and the diseased organ. 
Ischemic heart disease causes chest pain (angina pectoris), shortness of breath and 
arrhythmias, and may lead to myocardial infarction (MI), also known as heart attack. 
However, approximately 50% of cardiac deaths are sudden, without any previous symptoms 
(12). Carotid artery disease causes paralysis, loss of consciousness, headache and other 
neural symptoms, and may lead to stroke. PAD causes numbness, pain and intermittent 
claudication. Chronic kidney disease is associated with a slow loss of kidney function which 
is usually asymptomatic; symptoms appear in the late stage of the disease, for example 
swelling and loss of appetite. 
The diagnosis of the ASCVD is based on clinical status and the results from several tests. 
The electrocardiogram (ECG) measures electrical activity of heartbeat, and changes in 
normal ECG indicate cardiac abnormalities. An exercise stress test can be used for stable 
patients to provoke changes in ECG. Imaging methods, including angiogram and a computer 
tomography scan can be used to visualize diseased arteries. These provide information about 
the severity of the disease and are used to choose the most appropriate preventative treatment 
strategies to avoid further cardiovascular events and deaths (3). 
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2.1.3 Risk factors and biomarkers 
There some non-modifiable conventional risk factors for atherosclerosis i.e. advanced age, 
male gender, family history and genetic abnormalities. The modifiable risk factors include 
dyslipidemia, hypertension, glycemic control in diabetes, and insulin resistance. 
Behavioural risk factors have crucial roles as risk factors for CAD, for example smoking, 
Western type diet, obesity, physical inactivity, and excessive alcohol consumption. Non-
smoking, physically active people with healthy diet, moderate alcohol consumption and no 
abdominal adiposity have been found to display a 86% lower risk for primary MI in 
comparison to people who do not engage in these healthy behaviours (21). Dyslipidemia, 
hypertension, type 2 diabetes, and insulin resistance can all be managed by modifying these 
behavioural risk factors (3).  
Dyslipidemia includes high total cholesterol, LDL-C, triglycerides (TGs), and low high 
density lipoprotein cholesterol (HDL-C). The recommended levels for LDL-C vary 
depending on the patient´s CVD risk category. In the general population, LDL-C is 
recommended to be <3.0 mmol/L (<116 mg/dL) but the value is much lower for very high 
risk patients i.e.  LDL-C <1.4 mmol/L (<55 mg/dL) (3). The LDL-C concentration in the 
inner layer of the arterial wall, the intima, is similar to LDL-C concentration in plasma (22). 
The physiological plasma LDL-C concentration is low, around 1.0 to 1.5 mmol/l; when this 
limit is exceeded, LDL particles begin to accumulate into arterial intima (22-25). Despite the 
provision of intensive LDL-C lowering therapies, a residual risk remains (26). 
Approximately every second patient who has concentrations of total cholesterol and LDL-C 
that are currently considered normal, and no other risk factors for CAD, still has calcified 
plaques when he/she reaches middle-age (27). It has been suggested that lower target levels 
for total cholesterol and LDL-C might more efficiently prevent atherosclerosis as well as the 
earlier adoption of lifestyle and medical interventions (28).  Certain phenotypes of LDL, 
such as small dense LDL, oxidized LDL (oxLDL) and lipoprotein (a) (Lp(a)), are considered 
particularly pathogenic, thus the measurement of only LDL-C levels does not fully capture 
the LDL-related risk of ASCVD (29,30). In fact, additional measurements that are related to 
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the pathophysiological functions of LDL particles may help to unveil the actual ASCVD risk 
that is not explained by conventional risk factors.  
Interest in finding novel biomarkers has been increasing, and recently plasma sphingolipids 
have been suggested to be related to atherosclerosis and cardiovascular deaths (31-34). 
Sphingolipids are molecules containing a sphingoid base, mostly 18 carbon-long with one 
double bond (C18:1 or simply 18:0) and a fatty acyl group. To allow an easier nomenclature 
of sphingolipids, the sphingoid base is usually left out, for example, ceramide 18:1/16:0 is 
ceramide (Cer) 16:0. Sphingomyelins (SM) and ceramides are subgroups of sphingolipids 
that are found in LDL particles and their structure will be discussed in chapter 2.3.3. 
“Lipoprotein structure”. Bioactive sphingolipids play a role in inflammatory signalling and 
apoptosis (35) and they are enriched in atherosclerotic plaques (36). 
Plasma Cer 18:0 and 18:1 levels have been shown to predict major cardiovascular events in 
population cohort (FINRISK 2002) (37). Similarly, the plasma Cer 18:1 concentration was 
found to associate with major adverse cardiac events and vulnerable plaques in the 
prospective ATHEROREMO IVUS-study (38). The LURIC study showed that plasma 
levels of Cer 16:0, 18:0 and 24:1, as well as plasma SM 16:0, 16:1, 24:1 and 24:2 
concentrations associated with cardiovascular mortality. Similarly, the amounts of 
ceramides 16:0 and 24:1 were found to predict future CAD deaths in three independent 
prospective studies (Corogene, BECAC and SPUM-ACS) (31). The predictive power of 
these lipids became stronger if these lipids were divided with the level of Cer 24:0 (31). 
Recently, authors have improved their earlier ceramide risk score, which now includes only 
three ratios, Cer 24:1 to Cer 24:0, two ceramide ratios for phosphatidylcholines (PCs); Cer 
16:0 to PC 16:0/22:5 and Cer 16:0 to PC 14:0/22:6, and one individual lipid, PC 16:0/16:0 
concentration (39). At present, while there are some inconsistencies in the results, it does 
seem that at least some ceramides and SMs are indicators of an increased risk for ASCVD. 
The future will show which kind of lipids or lipid ratios are best for ASCVD risk estimation 
and may be beneficial in the development of novel treatment strategies.  
Ethnicity is a genetic factor that has an effect on the ASCVD risk. For example, people 
originating from South Asia (India, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka) 
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have a higher risk for ASCVD than other ethnic groups (40). South Asians experience their 
first MI on average 10 years earlier and they have higher morbidity and mortality rates for 
ASCVD as compared to white Caucasians (41). South Asians have a higher prevalence of 
ASCVD risk factors and they have higher body fat percentage, however the high risk for 
ASCVD cannot be solely explained by these factors alone (42-44).  
Risk factors are evaluated with laboratory tests and blood pressure measurement. In addition, 
calculating risk scores can help to predict the risk of coronary heart disease and stroke, e.g. 
the Systematic COronary Risk Evaluation (SCORE) or FINNRISK-calculator. For example, 
FINNRISK-calculator evaluates the percentual risk to develop CAD/ MI or stroke in 10 
years. The prediction is based on age, gender, smoking, HDL-C, LDL-C, blood pressure, 
family history and possible diabetes. An elevation of the risk by 10% or higher is considered 
as a high risk for CAD/MI/stroke; for SCORE, the limit is 5%. In addition, polygenic risk 
scores will most probably become increasingly important in the future in the evaluation of 
risk to develop CAD as well as in the development of treatment strategies (45). 
2.1.4 Treatment 
When treating atherosclerosis, the management of modifiable risk factors is important. Non-
medical interventions include smoking cessation, adoption of a Mediterranean diet or some 
other healthy diet, weight loss if overweight, exercise and reducing alcohol consumption. 
To reduce LDL-C concentration to target levels, statins are the primary medication (3). 
Statins have been demonstrated to prevent MI and cardiovascular deaths, both in primary 
prevention and after MI (46-51). Statins inhibit the β-hydroxy β-methylglutaryl-CoA (HMG-
CoA) reductase, the rate limiting enzyme in cholesterol biosynthesis in the liver, which leads 
to an increase in the numbers of LDL-receptors (LDLR) on the surface of the liver, and 
reduced total and LDL-C concentrations in plasma. Ezetimibe can be an alternative or 
additive treatment to reduce LDL-C concentrations, if statins are not suitable or if target 
levels cannot be reached with statins alone (52,53). Ezetimibe prevents the dietary and 
biliary cholesterol absorption in the intestine (54). Since, less cholesterol is transported to 
the liver, similarly to the situation with statins, this leads to a reduction in intracellular 
cholesterol which promotes upregulation of LDLR expression, and thus reduces the plasma 
LDL-C level. Proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies 
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(mAb)s are new group of medicines that lower LDL-C dramatically; they are more effective 
in preventing CAD events when combined with statins than can be achieved with only statins 
alone (3,55-57). Circulating LDL particles bind to LDLRs on the surface of the liver, LDLRs 
are transported with LDL particles inside the hepatocytes, where LDL is released and LDLR 
is transported back to the surface of the liver. Plasma PCSK9 can bind to LDLR, which is 
transported to lysosomes where it is degraded, which lowers the amount of LDLRs on the 
surface of the liver, and increases the plasma LDL-C concentration (56). If PCSK9 antibody 
binds to PCSK9 in plasma and prevents a PCSK9-LDLR interaction in hepatocytes, LDLR 
is transported back to the surface of the liver, and the plasma LDL-C concentration declines.  
It has been estimated that a reduction of LDL-C by 1 mmol/l reduces major vascular events 
by 21% (58). Statins can reduce LDL-C by 20-40% depending both on which statin is 
administered and its dose (59). The most effective treatment to reduce LDL-C can be 
achieved when statins are combined with PCSK9 mAbs, resulting on average of an over 
50% further reduction in LDL-C (60,61) while ezetimibe combined with statins lowers LDL-
C only by a further 24% (62). 
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2.2 ATHEROGENESIS 
2.2.1 Historical view 
In 1910, Adolf Windaus, together with Karl Albert Ludwing Aschoff, observed that that 
human atherosclerotic aortas contained over 20-fold more cholesterol esters than normal 
aortas (63), Windaus was awarded a Nobel prize in 1928 for his scientific work with sterols. 
In 1913, Anitschkow and Chalatow demonstrated that feeding of rabbits and guinea pigs 
with a diet high in cholesterol or egg yolk induced lipid deposits in the arteries (64). 
2.2.2 Response-to-Retention hypothesis 
`Response-to-Retention hypothesis` is the leading theory for atherosclerotic plaque 
formation and it is supported by a wealth of scientific evidence (65,66). In addition to the 
Response-to-Retention hypothesis, there are two other hypotheses; Response-to-
Inflammation (67) or Response-to-Injury (68). The former highlights the role of low-grade 
inflammation in the artery wall, and the latter states that the initial event in atherogenesis is 
an injury of the endothelium. However, all these hypotheses are linked to each other, for 
example one of the first steps is invariably a lipid influx into the artery wall. Apolipoprotein 
B (apoB) containing LDL, small very low density lipoprotein (VLDL), intermediate density 
lipoprotein (IDL) and even small chylomicron remnants smaller than 70 nm can cross an 
intact endothelium and reach the tunica intima (69). Endothelial dysfunction enhances lesion 
formation, and it occurs most commonly at arterial curves and branches, where blood flow 
is disturbed; these are called atherosclerotic prone areas (70,71). 
The Response-to-Retention hypothesis suggest that retention or accumulation of apoB 
containing cholesterol-rich lipoprotein within arterial wall is the key initiating event in 
atherogenesis (Figure 1). Retained lipoproteins are modified in the intima by oxidation, as 
well as by proteolytic and lipolytic enzymes (66,72). The retention of the LDL particles in 
the intima depends both on the plasma LDL-C concentration and the features of the 
proteoglycans (73,74). These retained and modified lipoproteins trigger local inflammation 
attracting an influx of monocytes which subsequently differentiate into macrophages (5,6). 
Macrophages and smooth muscle cells avidly take up these lipoproteins leading to the 
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formation of foam cells and they also start to secrete proinflammatory mediators and 
enzymes (75). For example, CD4+ T cells are also recruited into the developing plaque (76). 
Over time, a more advanced lesion develops, having activated macrophages, T-cells and 
mast cells that induce local inflammation. Complex plaques are covered by a fibrous cap and 
have a necrotic core formed from cell debris, necrotic and apoptotic cells and cholesterol 
crystals. This progress from harmless “fatty streaks” to a destructive “vulnerable plaque” is 
described below.  
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Figure 1. Atherogenesis. LDL accumulates under the endothelial layer in tunica intima. 
Fatty streaks are visible to the naked eye and when they have developed into atheromas, 
plaques can rupture, causing thrombosis or blocking circulation in artery. The insert shows 
a vulnerable plaque and thrombus formation. 
29 
 
2.2.3 LDL binding to arterial proteoglycans 
Circulating LDL can enter the inner layer of the arterial wall, the intima, where LDL can 
bind to intimal extracellular proteoglycans leading to LDL retention (73,74,77). ApoB-100, 
the major apolipoprotein present in LDL particles, has segments of positively charged 
residues, lysine and arginine, that bind to the negatively charged carboxylic acid and sulfate 
groups of glycosaminoglycan chains of proteoglycans (78). Proteoglycans are proteins to 
which glycosaminoglycan chains are covalently attached and are a major component of the 
extracellular matrix.  
Glycosaminoglycans are bound to the core protein, for example in the case of versican, it 
can further bind via a linker protein to hyaluronic acid, forming large components in 
extracellular matrix. (Figure 2). 
 
Figure 2. Structure of proteoglycan-hyaluronic acid complex and LDL binding to 
proteoglycans. LDL can bind to intimal extracellular proteoglycans via an apoB-100 – 
proteoglycan interaction. 
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2.2.4 LDL oxidation 
When LDL particles are retained in the intima, they are exposed to modifying agents and 
enzymes. LDL can be oxidized by enzymatic or non-enzymatic catalysts, in a process 
involving reactive oxygen species (ROS). There is constant ROS production due to normal 
cell function and xenobiotic metabolism as well as due to the presence of pollutants, tobacco 
smoke and ionizing radiation etc. Thus, oxLDL causes endothelial dysfunction that has 
further pro-inflammatory and pro-atherogenic consequences but its concentration can be 
reduced by statin therapy (79,80). Minimally oxidized LDL particles can be recycled back 
to the circulation, and therefore the oxLDL concentration can be measured from plasma 
samples. The circulating oxLDL level is higher in patients having CAD and it is considered 
a biomarker for the disease (81). Instead, extensively oxidised LDL particles are recognized 
by scavenger receptors of intimal macrophages leading to foam cell formation (80).  
2.2.5 LDL aggregation 
In the intima, LDL particles are exposed to lipolytic, proteolytic and oxidative enzymes and 
agents. These modifications have a critical role in atherogenesis. Modified LDL particles are 
susceptible to aggregation and aggregated LDL particles cannot diffuse back to the 
circulation. LDL aggregates bind intimal proteoglycans more strongly than native or 
modified, non-aggregated LDL particles (82). LDL aggregation can be induced in vitro by 
various enzymes or oxidative agents, most commonly by acid sphingomyelinase (SMase), 
neutral SMase, phospholipase A2 (PLA2), α-chymotrypsin, or CuSO4 oxidation. Of these, 
only acid SMase forms large LDL aggregates (>3,000 nm), whereas even after overnight 
incubations, other agents form only small LDL aggregates (30-200 nm) (83). In the arterial 
intima, acid SMase can hydrolyse LDL-SM to ceramide, which can lead to LDL aggregation 
and promote the initiation and progression of atherosclerosis (36,84,85). Indeed, human 
atherosclerotic plaques have been demonstrated to contain aggregated lipoprotein particles 
(86,87) and particularly the largest aggregates are enriched in ceramides, the lipolytic 
product of SM hydrolysis by SMase (36,88). In rabbits, it has been shown that after only two 
hours of bolus injection of human LDL, LDL can accumulate in intima, but also forms LDL 
aggregates in focal areas of the intima (36). Because LDL can become aggregated very 
rapidly in the intima after injection into the circulation, oxidation is not likely to be the reason 
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for this fast in vivo aggregation and arterial SMase has been shown to hydrolyze LDL-SM 
(36), and thus SMase is in vivo one of the most potent cause of LDL aggregation.  
Furthermore, aggregated LDL particles promote extensive foam cell formation (89,90) by 
mechanisms that have been suggested to involve the catabolism of aggregated LDL in the 
extracellular acidic hydrolytic compartment, a process observed both in vitro and in vivo 
(91,92). Aggregated LDL particles have also the potential to induce inflammation in the 
intima and to promote plaque destabilization (87,93). LDL modified by the combination of 
protease and cholesteryl esterase releases free fatty acids (FFA)s, of which oleic acid and 
linoleic acid particularly induce interleukin (IL)-8 secretion from endothelial cells (94). 
Furthermore, IL-8 triggers adhesion and migration of circulating monocytes into the intima 
(95). 
2.2.6 Inflammation in atherogenesis 
Human atherosclerosis is driven by lipid accumulation, which leads to chronic local 
inflammation of arterial intima. The modification of any apoB-containing lipoprotein can 
induce local innate and adaptive immune responses in the intima (96,97). The lipoproteins 
can activate inflammatory cells in the intima, after which these cells start to secrete pro-
inflammatory cytokines and chemokines that activate both endothelial cells and circulating 
leucocytes (98,99). This results in the further recruitment of inflammatory cells of myeloid 
origin, especially monocyte migration into the intima. In the intima, the monocytes become 
transformed into macrophages that secrete enzymes and agents having the potential to 
modify lipoproteins (100). Cellular activation and lipoprotein modification lead to the 
creation of a vicious cycle, in which modified lipoproteins can provoke cells to secrete higher 
amounts of enzymes and agents to further modify lipoproteins. Finally, foam cells undergo 
some form of cell death, releasing their lipid contents into the extracellular fluid, and if 
removal of cell debris by new macrophages does not occur, this can lead to the formation of 
a mature atherosclerotic plaque with a necrotic core (101). 
Pro-inflammatory macrophages activate adaptive immunity mainly by helper T cells (CD4+). 
Antigen presenting cells can activate helper T cells by presenting LDL-derived peptides and 
further T cells activate pro-inflammatory pathways in the plaque niche (102). In addition, 
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many other immune cells are known to be present in human atherosclerotic plaques, e.g. 
natural killer cells, mast cells, and eosinophils (103). 
2.3 LIPOPROTEIN / LDL METABOLISM 
2.3.1 Historical view 
Konrad Bloch and Feodor Lynen were awarded the Nobel Prize in Physiology and Medicine 
in 1964 "for their discoveries concerning the mechanism and regulation of the cholesterol 
and fatty acid metabolism." In 1971, the Framingham prospective cohort study associated 
serum cholesterol with increased risk of cardiovascular disease (104). Michael Brown and 
Joseph Goldstein were awarded the Nobel Prize in Physiology or Medicine in 1985 “for their 
discoveries concerning the regulation of cholesterol metabolism”. 
2.3.2 Lipoprotein structure 
The purpose of lipoproteins is to transport hydrophobic lipid molecules in hydrophilic fluids, 
such as blood, lymph or extracellular fluids. Lipoproteins consist of hydrophobic core lipids 
with an amphipathic surface monolayer of lipids, and apolipoproteins. The major 
lipoproteins are described in Table 1, including their main core lipid composition and 
apolipoproteins attached to each lipoprotein. The hydrophobic core lipids are 
triacylglycerols (TG)s and cholesteryl esters (CE)s (Figure 3); the ratio of these compounds 
depends on the lipoprotein particle. The surface lipids are mainly phospholipids and 
unesterified cholesterol (UC). Phospholipids are further classified as PCs, SMs, and their 
hydrolysis products, lysophosphatidylcholines (LPC)s and ceramides (Figure 4). In 
addition, minor lipids, for example phosphatidylethanolamine (PE), phosphatidylinositol 
(PI) and phosphatidylserine (PS) are found in these particles. 
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Table 1. Human lipoproteins and their main core lipid and apolipoproteins. Very low 
density lipoprotein, VLDL, low density lipoprotein, LDL, intermediate density lipoprotein, 
IDL, lipoprotein (a), Lp(a), high density lipoprotein, HDL. Modified from (105). 
Proatherogenic lipoproteins Anti-atherogenic 
lipoproteins 
 Exogenous lipid transport 
system 
Endogenous lipid transport system 
Particle Chylomicron Chylomicron 
remnant 
VLDL VLDL 
remnant 
(IDL) 
LDL Lp(a) HDL Discoidal 
nascent 
HDL 
Radius 
(nm) 
1000-80 100-50 70-30 30 20 20 8.5-10 5 
Major 
core lipid 
TG CE TG TG CE CE CE no core 
Major 
apolipo-
proteins 
A 
B-48 
 
C 
E 
 
A 
B-48 
 
 
E 
 
 
B-100 
C 
E 
 
 
B-100 
 
E 
 
 
B-100 
 
 
 
B-100 
 
 
a 
A 
 
 
C 
E 
 
A 
 
 
 
Site of 
synthesis 
intestine circulation liver circulation circulation liver intestine 
circulation 
liver 
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Figure 3. LDL surface lipid structures. Triacylglycerides have a glycerol backbone and 
three ester- linked fatty acid chains. This triacylglycerol has a saturated fatty acid, palmitate 
(18:0) at sn1-position, a monounsaturated oleic acid (18:1) at sn2-position, and a 
polyunsaturated arachidonic acid at sn3-position. Cholesterol esters have one fatty acid 
linked to cholesterol with an ester bond.  
 
Figure 4. LDL surface lipid structures. Cholesterol has a hydrophilic hydroxyl group (-
OH), four hydrophobic steroid rings and a hydrocarbon tail. Phosphatidylcholines have a 
glycerol backbone and two ester-linked fatty acids and a hydrophilic phosphocholine head 
group. Lysophosphatidylcholines have a similar structure, but they have only one fatty acid 
linked to glycerol. Sphingomyelins have a sphingosine backbone, a phosphocholine head 
group and one fatty acid linked to it via an amide bond. Sphingomyelinase can break down 
sphingomyelin to ceramide and phosphocholine. 
Cholesterol ester 
Triacylglycerol 
Phosphatidylcholine 
Lyso-phosphatidylcholine 
Sphingomyelin Ceramide 
Cholesterol 
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2.3.3 LDL particle structure 
The LDL particle structure is described in Figure 5. Like other lipoproteins, LDL particles 
have a hydrophobic core that in the case of LDL, is rich in CEs. The major component of 
LDL particle is CE (~40%, wt/wt), followed by phospholipids (PL) (~20 %), apoB-100 
(~20%), UC (~10%) and TGs (~5%). The surface monolayer of LDL particles contains 
mainly two types of phospholipids; about 450 molecules of PC and about 185 molecules of 
SM. Two-thirds of about 600 molecules of UCs are located on the surface and one-third in 
the core. The LDL particle surface also contains small amounts of other lipids, including 
LPC (about 80 molecules), PE (about 10 molecules), ceramides (about 2 molecules) and 
some PI (106). The principal structural apolipoprotein of LDL is a single copy of apoB-100 
that surrounds the particle and interacts with surface lipids. The core of the particle consists 
predominantly of CEs (about 1600 molecules) and a relatively small amount of triglycerides 
(about 170 molecules) (106). 
  
Figure 5. LDL structure. LDL particle has a hydrophobic core and amphipathic surface 
lipids. A single copy of apolipoprotein B-100 (apoB-100) surrounds the particle. ApoB-100 
has domains rich in amphipathic α-helices and β-sheets. Modified from (106). 
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2.3.4 Exogenous lipid metabolism 
Almost all i.e. 95%, of the dietary fats are triglycerides (TGs), the remaining 5% are 
phospholipids (PLs), CEs, FFAs and fat-soluble vitamins. Dietary TGs are converted in 
stomach and duodenum by gastric lipase to monoglycerides and FFAs, similarly CEs are de-
esterified to UC and FFAs. 
FFAs, monoglycerides and UC form micelles with bile acids, and can then be absorbed from 
intestine into enterocytes. In enterocytes, these lipids are re-esterified and packaged into 
chylomicrons. Chylomicrons are the largest lipoproteins, having one apoB-48 protein on the 
surface of the particle. TGs and CEs form the hydrophobic core with PLs and UCs as the 
hydrophilic monolayer on the surface of the lipoprotein, where the apolipoprotein is 
attached. Chylomicrons are then transported via the lymphatic system into the circulation. 
ApoC-II proteins from VLDL and HDL become attached to chylomicrons in the circulation 
and they activate endothelial lipoprotein lipase (LPL) in muscle and adipose tissue 
capillaries (107). LPL hydrolyses TGs to FFAs and glycerol that are used for energy 
production or storage (108). The majority i.e. 70-80%, of chylomicron-TGs are hydrolysed 
with a few minutes after they gain access to the circulation. As the core becomes smaller, 
the surface material of chylomicrons folds and is attached to HDL particles. The lipolyzed 
10-fold smaller chylomicron remnants lose apoC-II with this being replaced by apoE from 
other apolipoproteins. ApoE is recognized by LDLR of hepatocytes and chylomicron 
remnants can therefore be taken up into the liver (109).  
In hepatocyte lysosomes, chylomicron remnant lipids are hydrolysed to FFAs, glycerol and 
UC; apolipoproteins are also hydrolysed to amino acids. UC is then transported to the 
cytosol, from where it is secreted to bile fluid as a UC or bile acids. Almost all (95%) of the 
bile acid secreted to the intestine will be recycled back to the liver through the enterohepatic 
circulation (110). In contrast, UC absorption from intestine varies between individuals from 
25 % to 80 % (111). Because cholesterol cannot be hydrolysed in human cells, the only 
excretion route is via the intestine as bile acids (one third) or as UCs (two third) to faeces 
(112).  
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2.3.5 Endogenous lipid metabolism 
Hepatocytes produce VLDL particles that transport TG and CE back to the circulation. 
VLDL particles has typically three types of apolipoproteins, apoB-100, apoE, and apoC-II, 
and the core is rich in TGs as compared to CEs. VLDL metabolism is similar to 
chylomicrons, TGs are lipolyzed by LPL and as the core becomes smaller, cholesteryl ester 
transfer protein (CETP) moves CEs from HDL to VLDL (113).  ApoC-II is released from 
the surface, the core is enriched in CEs, and the particle is now called a VLDL remnant or 
an intermediate density lipoprotein (IDL).  VLDL remnants can be taken back into the liver 
by LDLRs that recognize both apoB-100 and apoE. Approximately 50% of VLDL remnants 
are taken into the liver and the other half rapidly lose their apoE, such that the core consists 
now mostly of CEs, and the particle is called LDL (114). (Figure 6) 
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Figure 6. Endogenous lipid metabolism. Very low lipoprotein particles (VLDL) are 
produced in the liver and secreted into circulation. Lipoprotein lipase (LPL) hydrolyses 
triglycerides (TG)s from VLDL particles and the particle core becomes smaller. TGs are 
used for energy production in muscle tissue or stored in adipose tissue depending on the 
metabolic state. Cholesteryl ester transfer protein (CETP) transports cholesterol esters (CE)s 
from high density lipoprotein (HDL) particles to VLDL. The core becomes enriched with 
CE and is called an intermediate density lipoprotein (IDL). IDL further loses TGs and it 
becomes a low density lipoprotein (LDL) particle. IDL and LDL particles can be captured 
by the liver via the LDL-receptor (LDLR) or they can be taken up by the peripheral tissues. 
Figure was created with BioRender.com 
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Most of LDL particles are taken back to the liver by apoB-100 - LDLR interactions or 
hepatic scavenger receptors, the remaining 30 % are taken up by extrahepatic tissues. 
Extrahepatic cells can take up LDL via the LDLR and hydrolyse CE to UC that can be used 
as a structural component e.g. for the synthesis of biological steroids (115). LDL can be 
taken up into peripheral tissues and in normal circumstances, excess cholesterol is 
transported to the lymphatic system from where it is passed back into the circulation (116). 
All cells in the human body have the capability to produce cholesterol.  
Lp(a), is LDL that contains apoprotein (a). Apo(a) is a large glycoprotein, having a high 
homology with plasminogen. Because of this homology, Lp(a) inhibits fibrinolysis, by 
competition with plasminogen binding, and thus it may increase blood clotting (117,118). 
However, a recent study revealed that ex vivo clot analysis was not affected by Lp(a) (119).  
Lp(a) is an independent risk factor for CAD, and it is not effectively reduced by LDL-C 
lowering medication (120).  
HDL particles have the ability to take cholesterol from cells back to the circulation and the 
liver, in a process called reverse cholesterol transport. HDL metabolism is complex, and a 
heterogeneous group of HDL particles have been identified. HDL can bind to scavenger 
receptor class B type 1 (SR-B1) receptors in the liver, or transfer cholesterol to apo-B 
containing proteins by CETP (114).  
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2.4. NUTRITION AND LIPID METABOLISM 
2.4.1 Historical view 
The diet-heart hypothesis suggests that reducing dietary fats reduces plasma cholesterol, and 
thereby reduces the ASCVD risk. The hypothesis was proposed by Ancel Keys in the 1950s 
and in 1980s he published the results from Seven countries study revealing the clear 
correlation between dietary saturated fats and coronary mortality (121). In 1968, it was 
thought that dietary cholesterol, which is present in high amounts in foods containing 
saturated fats, increased plasma cholesterol, and was the main dietary risk factor for 
atherosclerosis (122).  The hypothesis has been modified since then from total saturated fat 
or cholesterol consumption to a recommendation of replacing saturated fats with 
polyunsaturated fats (PUFAs) (3,123,124). 
2.4.2 Dietary components and atherosclerosis risk 
It is estimated that dietary factors are linked to 11 million deaths (22 % of all deaths) every 
year and 255 million disability adjusted life years (15% of all disability adjusted life years) 
(125). Diet is also an important part of prevention and treatment of ASCVD, since it a good 
way to modify risk factors of the disease (126,127). Replacing dietary saturated fats with 
polyunsaturated fats has been shown to decrease total cholesterol, LDL-C, and triglyceride 
concentration in plasma and the incidence of major cardiovascular events (128-130). 
Replacing saturated fat with polyunsaturated fats, predominantly linoleic acid and α-
linolenic acid, or with monounsaturated fats, predominantly oleic acid, is more favourable 
than replacing saturated fat with carbohydrates (128). Polyunsaturated fats have the most 
beneficial effect on total and LDL-C (128). The Prospective Urban Rural Epidemiology 
(PURE) study disputed the harmfulness of saturated fats (131), and this triggered a lively 
discussion. In the PURE study, the authors concluded that total fat intake had no effect on 
cardiovascular health or even that the effect might be beneficial, because they had found an 
association between higher intake of saturated fats and a lower risk for stroke and total 
mortality (131). The PURE study has been widely criticised, the authors did not qualify the 
type of carbohydrates and the majority of the study subjects came from low-income 
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countries, where the diet consists of white rice and many of the participants suffered from 
undernutrition. (132,133). The conclusions of the PURE study were based on baseline 
dietary information, collected from food frequency questionnaires, that are known to 
underestimate food intake, especially fat intake (134). 
From a mechanistic standpoint, it is known that PUFAs reduce VLDL secretion from liver 
because they are more prone for oxidation, which leads to the degradation of apoB-100 
(135). After these discussions, current recommendations still emphasize that saturated fats 
should be avoided and replaced with polyunsaturated fats (3,123,124).  
The diet-heart hypothesis originally postulated that dietary saturated fats and cholesterol 
increase plasma cholesterol levels and the risk for CAD (121,122). The hypothesis is no 
longer so straightforward, the inter-individual variations in how much cholesterol is 
absorbed from the intestine and feedback response of endogenous cholesterol synthesis have 
divided individuals into hyper-responders and hypo-responders to dietary cholesterol (136). 
The dietary cholesterol intake is recommended to be less than 300 mg/day, especially among 
individuals with high plasma cholesterol levels (3). 
The dietary fatty acid composition directly affects the plasma fatty acid composition. For 
example, a high intake of n-3 PUFAs, such as fatty fish (containing eicosapentaenoic acid, 
EPA and docosahexaenoic acid, DHA) increases the levels of these PUFAs in plasma CEs, 
TGs and PLs; the consumption of Camelina sativa oil (containing α-linoleic acid), increases 
plasma α-linoleic acid in plasma CEs, TGs and PLs (137). 
A number of randomized, placebo controlled, double blind clinical trials have shown that 
food products supplemented with plant stanol esters can lower plasma LDL-C levels on 
average by 10-15 % if there is a 2-3 g/day plant stanol intake (138,139). This kind of decrease 
in LDL-C achievable by eating a plant stanol ester enriched spread is as effective in reducing 
estimated cardiovascular risk as adherence to the Mediterranean diet (140). Plants do not 
contain any cholesterol, but they have phytosterols; plant stanols and sterols. There is a small 
quantity of plant stanol esters in the human diet with their main source being whole-grain 
foods, and some amounts are also present in other foodstuffs, for example in vegetable oils, 
fruits, vegetables, and nuts (141). Chemically, these sterols/stanols are very similar to 
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cholesterol (Figure 7), but in the human body, they act very differently. While 25 to 80 % 
of cholesterol is absorbed from the intestine, plant sterols are hardly absorbed at all, only 
about 0.5 % and plant stanols, even less i.e.  by 0.05% (142). Plant stanols and sterols have 
a dual effect in the intestine, they reduce both dietary cholesterol absorption and bile 
cholesterol reabsorption. The daily intake of plant stanols in the Finnish population is 
relatively small, for plant stanol esters, it is 24 mg/day for men and 17 mg/day for women, 
and for plant sterols about 305 mg/day and 237 mg/day (141). Thus a biologically effective 
dose (2-3 g/day) can only be achieved with products enriched with phytosterols, most 
commonly plant stanol-enriched spread (3).  
When it comes to diet, if the individual leaves something out, then it needs to be replaced 
with something else. As stated earlier, the most beneficial effect can be achieved by 
substituting saturated fats with unsaturated fats. (3,123,124) The other macronutrients which 
can replace saturated fats are carbohydrates and proteins. Carbohydates, especially a high 
intake of sugars, like fructose, increases plasma LDL-C, TG and decreases HDL-C (143-
145), by increasing de novo lipogenesis. The regular consumption of sugar-sweetened 
beverages in women is associated with a higher risk for MI (146). Consumption of high or 
low carbohydrate diets are both unhealthy, as also low carbohydrate, high fat diets have been 
shown to increase LDL-C (147). Similar to the situation in carbohydrates and fats, also in 
proteins, quality matters. Plant based-protein and low carbohydrate diets are associated with 
the lowest CVD mortality (148), while animal based-protein and low carbohydrate diets 
have been linked with higher CVD and CVD mortality (148,149). 
Sodium intake is associated with blood pressure and CAD risk (150,151). The majority of 
dietary salt comes from processed foods, and thus the consumption of unprocessed foods is 
recommended (123). In contrast, dietary potassium has beneficial effects on blood pressure 
and CAD risk (152). The main source of potassium in diet is fruits and vegetables, and a 
high consumption of these foodstuffs is recommended (123).  
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Figure 7. Chemical structure of cholesterol ester, plant stanol ester and plant sterol 
ester. Cholesterol is produced in humans, whereas plant sterol esters and plant stanol ester 
are synthesized only in plants.  
The consumption of several vitamins has been associated with reduced CAD risk in 
observational studies, with most evidence for vitamins A, E and D. However, interventional 
trials have failed to confirm these findings, and, in contrast, have even suggested that 
supplemented vitamins A and E are harmful (153,154). Therefore, there are no 
recommendations of vitamin supplementations for CVD prevention (123). A higher dietary 
fibre intake is associated with a lower risk for CVD and therefore a higher intake of fibre is 
recommended (123,155).  
2.4.3 Foods, dietary patterns and atherosclerosis risk 
People eat food, not macronutrients, which makes it hard to demonstrate causal associations 
between nutrients and disease risk. The Mediterranean diet has been the most extensively 
studied as a dietary pattern to prevent CVDs (156). It has been shown to decrease total 
cholesterol levels and the CVD risk in both Southern European (157) and Eastern European 
populations (158). The Prevención con Dieta Mediterránea (PREDIMED) trial indicated that 
participants assigned to a Mediterranean diet, supplemented with extra olive oil or nuts had 
Cholesterol 
ester 
Plant sterol 
ester 
Plant stanol 
ester 
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a significantly lower incidence of major CV events compared with those who were on a 
control (low-fat) diet, with a relative difference of 30% (130,157,159). The Scandinavian 
alternative to the Mediterranean diet is the healthy Nordic diet that includes whole grains, 
fruits and vegetables, berries, low-fat dairy products and fatty fish (160). The healthy Nordic 
diet has been associated with a reduction in blood pressure, LDL-C levels, and obesity in 
type 2 diabetic patients (161) as well as in the prevention of strokes (162). 
Both Mediterranean and healthy Nordic diet include a limited intake of red meat. A very 
recent study suggested that a higher consumption of red and processed meat would be 
associated with a higher ischemic heart disease risk, whereas higher consumption of cheese, 
eggs, and yogurt exerted an inverse effect (163). Plant products were not analysed in that 
study, and they may have beneficial effects as compared to animal products (164). Since 
both meat and cheese are high in saturated fats, the authors speculated that the difference 
could be attributable to the level of carnitine in meat; this quaternary amine can be 
metabolized to trimethylamine oxide, and has been shown to associate with an increased risk 
of atherosclerosis (163,165). 
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3 AIMS OF THE STUDY 
 
This study aims to define LDL aggregation susceptibility as a novel modifiable and 
measurable factor associated with ASCVD risk, including interventions to affect LDL 
aggregation susceptibility. 
1. To develop a method to measure the LDL aggregation susceptibility from plasma 
samples. (I) 
2. To study if the lipid composition of LDL particles mechanistically explains the inter-
individual variance in the LDL aggregation susceptibility. (I) 
3. To examine if the LDL aggregation susceptibility is associated with atherosclerosis 
and if it predicts future cardiovascular deaths. (I) 
4. To investigate if ethnicity affects the LDL aggregation susceptibility in an Ethnicity 
study investigating subjects with either South Asian or white Caucasian origins. (II) 
5. To explore if the healthy Nordic diet or extra calories from saturated fat, unsaturated 
fat or carbohydrates affect the LDL aggregation or other quality properties of LDL. 
(III) 
6. To investigate if PCSK9 monoclonal antibody treatment exerts a beneficial effect 
on the LDL aggregation susceptibility. (I) 
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4 MATERIALS AND METHODS 
4.1 PATIENT COHORTS 
The patient cohorts included in this thesis are presented in Table 2. and described in more 
detail below. 
Table 2. Patient cohorts.  
Cohort 
Official Title 
Study type, 
Time 
Perspective 
Ref. Clinical trial 
nro. 
Study 
Population cohort, n=100 
Health 2000 Health examination 
study 
 
Epidemiological 
 
(166)  I 
Healthy Nordic diet 
intervention, n=57 
The Effect of Nordic 
Recommended Diet on the    
Features of Metabolic Syndrome  
- Multicentre Study (SYSDIET) 
 
Interventional, 
Randomized, 
Parallel 
Assignment 
(167) NCT00992641  I 
Patients with coronary 
stenosis, n=48    
Genetic Predisposition of 
Coronary Artery Disease  
- The COROGENE Study 
 
Observational, 
Prospective 
(168) NCT00417534 I 
Phase ll trial for PCSK9 
monoclonal antibody, n=40 
Study of the Safety and Efficacy 
of MPSK3169A in Patients With 
Coronary Heart Disease or 
High Risk of Coronary Heart 
Disease 
-The EQUATOR Study 
 
Interventional, 
Randomized, 
Parallel 
Assignment, 
Double blinded 
Placebo-
controlled 
(169) NCT01609140 I 
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Ethnicity study, n=24 
Exenatide and Brown Adipose 
Tissue (exe01) 
 
Interventional, 
Single group 
Assignment, no 
blinding 
Unpub NCT03002675 II 
Hypercaloric diet, n=36 
Effects of Overfeeding Followed 
by Weight Loss on Liver Fat   
Content and Adipose Tissue 
Inflammation 
 
Interventional, 
Randomized, 
Parallel 
Assignment, no 
blinding 
(170) NCT021333144 III 
 
4.1.1 Health 2000 Health Examination Survey 
Health 2000 survey is a large Finnish epidemiological survey, carried out from fall 2000 to 
spring 2001 by the National Public Health Institute (166). The total survey included 8028 
participants, representing the Finnish population. Samples from 100 participants, 50 % male 
and 50 % female, aged 33 to 48 years that were largely healthy when examined in this study. 
The clinical characteristics for these 100 participants are presented in Study I, Table 1. 
4.1.2 SYSDIET study 
SYSDIET study was randomized, controlled, interventional, parallel assignment study 
performed in six centres: Kuopio and Oulu (Finland), Lund and Uppsala (Sweden), Aarhus 
(Denmark) and Reykjavik (Iceland) (167). The participants had features of metabolic 
syndrome without diabetes and they were randomized to eat either Healthy Nordic diet or 
Control diet. All the participants were obese (body mass index, BMI 28-35 kg/m2) and had 
two of the other international diabetes federation criteria for metabolic syndrome (171). The 
Healthy Nordic diet included fruits and vegetables, wholegrain products, berries, rapeseed 
oil, low-fat dairy products and fish three times per week. The control diet was based on the 
average Nordic diet. The intervention lasted for 18-24 weeks. The study included total of 
166 individuals that completed the study, of which 55 samples from Finland were available 
for this study; 33 samples from the Healthy Nordic diet group and 24 samples from the 
Control group, from baseline and the end of the intervention. 
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4.1.3 Corogene study 
Corogene study was an observational, prospective study investigating Finnish patients with 
CAD (168). The study examined a total of 5295 patients and the samples were collected 
from summer 2006 to spring 2008. Coronary angiography was performed in all patients and 
blood samples were taken. For this study, 48 samples from nested case-control sub-cohort 
of the Corogene study (31) were available, these included data from the national death 
certificate registry. The patients in this study were all male, non-diabetic, and having at least 
50 % stenosis in their coronary arteries. Twenty-four of these samples were from patients 
that had died during an average follow-up period of 2.5 years, and matching controls (n=24) 
were chosen from the group that experienced no cardiovascular events during the follow-up 
time. 
4.1.4 EQUATOR study 
EQUATOR study was a randomized, double-blind, phase 2 clinical study to investigate a 
fully human immunoglobulin G1 PCSK9 mAb (RG7652, Genentech, South San Francisco) 
(169). The study was performed from spring 2012 to summer 2013 in 9 countries. PCSK9 
mAb or placebo was subcutaneously injected once, and samples were collected before and 
29 days after the treatment. The study originally included 248 patients but samples from 40 
patients were used in this study (PCSK9, n=25 and placebo, n=15).  
4.1.5 Ethnicity study 
This study was a part of a clinical trial which had been performed in the Netherlands from 
fall 2016 to spring 2018. (Janssen & Nahon et al., in preparation) All the study participants 
were healthy Dutch males, 12 white Caucasians and 12 South Asians. The South Asian 
participants had all 4 grandparents of South Asian descent. Plasma samples were collected 
after overnight fasting and body composition was measured. 
4.1.6 Hypercaloric diet study 
Hypercaloric diet study was originally designed to investigate non-alcoholic fatty liver 
disease and included 28 participants (170). For this study, plasma samples from 26 
participants at the baseline and at the end of the study were available. The study was an 
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interventional, randomized, parallel-assigned study, where the participants ate 1000 extra 
calories per day for three weeks. The extra calories came predominantly from saturated fats 
(SAT group, n=13), unsaturated fats (UNSAT group, n=11) or simple sugars (CARB group, 
n=12).  
4.1.7 Ethical statement 
Written informed consent was obtained from all volunteers after the nature and potential 
risks of the study had been explained to them. All study protocols had been approved by 
local institutional review boards/ethics committees and the studies were conducted in 
accordance with the principles of the Declaration of Helsinki (172). 
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4.2 LABORATORY METHODS AND MATERIALS 
The main materials and methods that were used in this study are described in Table 3. 
Detailed materials and methods can be found in studies I-III. 
Table 3. The main materials and methods that were used to this study.  
Method Reference Study 
LDL isolation by ultracentrifugation (173,174) I, II, III 
LDL modification (82) I, II, III 
Dynamic light scattering (83,175) I, II, III 
Lipid extraction (176) I, II, III 
Mass spectrometry ESI-MS (177-180) I, II, III 
LDL binding to proteoglycans (181,182) III 
Circular dichroism (83,183) I 
Cell culture (93,184-186) I 
Mouse models (187) I 
Statistical methods - I, II, III 
ELISA and enzymatic assays - I 
 
4.2.1 LDL isolation by ultracentrifugation 
LDL (density = 1.019 to 1.063 g/ml) was isolated from frozen or fresh plasma/serum samples 
by KBr (potassium bromide) or D2O (deuterium oxide) sequential ultracentrifugation 
(173,174). In Study I, KBr was used in the isolation of all of the samples and after 
standardizing the protocol for D20, D20 isolation was used (Study II and Study III). LDL 
concentrations for isolated LDL samples were expressed as protein concentrations measured 
by the bicinchoninic acid assay (BCA) protein assay (Pierce, Rockford, USA) or as the 
apoB-100 concentration as determined by ELISA (Mabtech, Nacka, Sweden). ApoB-100 
measurements were done only for Health 2000 Health Examination Survey samples and 
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Sysdiet samples (Study I), after which the determination of the LDL protein with the BCA 
assay was found to correlate well with the amounts of apoB and BCA assay was used in all 
of the other samples. 
4.2.2 LDL modifications 
In the assay of LDL modification, KBr isolated plasma samples were first dialyzed 
extensively against a suitable buffer. Initially, when developing LDL aggregation 
susceptibility measurement, several agents were tested that have been shown to cause LDL 
aggregation (82). LDL oxidation was induced with 5 µM CuSo4 in 20 mM Tris-HCl, pH 7.4, 
containing 150 mM NaCl and 2 mM CaCl2 and 2 mM MgCl2. Proteolysis of apoB-100 was 
induced with 0.1 mg/ml α-chymotrypsin from bovine pancreas (Sigma-Aldrich, Missouri, 
USA) in 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 2 mM CaCl2 and 2 mM 
MgCl2. In the lipolysis of LDL, 50 mU/ml PLA2 from bee venom (Sigma-Aldrich, Missouri, 
USA), 200 mU/ml neutral SMase from Bacillus cereus (bcSMase, Sigma-Aldrich, Missouri, 
USA), or 75 µg/ml human recombinant acid SMase (a kind gift from Genzyme, Study I or 
produced in house, Study II) were used. PLA2 and bcSMase were incubated with LDL 
particles in 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 2 mM CaCl2 and 2 mM 
MgCl2, and human recombinant SMase (hrSMase) in 20 mM 2-(N-morpholino) 
ethanesulfonic acid (MES) buffer, pH 5.5, containing 150 mM NaCl and 50 µM ZnCl2. 
PLA2 hydrolyses the fatty acid of PLs in the sn-2 position, resulting in the formation of FFA 
and LPC. SMase hydrolyses the phosphocholine head group of SM resulting in the 
production of ceramide and phosphocholine. SM is hydrolysed almost completely to 
ceramides within one minute, after which LDL starts to aggregate. In-house hrSMase was 
produced in collaboration with Associate Professor Olli Ritvos, University of Helsinki. 
(Study II and III) 
4.2.3 Dynamic light scattering 
The LDL particle size in native stage and LDL aggregates was detected with dynamic light 
scattering (DLS) (83,175). DLS is based on Brownian motion, defined as “the random 
movement of particles in a liquid due to the bombardment by the (solvent) molecules that 
surround them”. Large particles have slow Brownian motions whereas smaller particles 
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move more quickly. In Study I, DLS Zetasizer Nano (Malvern Instruments, Malvern Works, 
UK) was used with cuvettes that were manually changed between measurements. The 
samples were incubated at 37°C between the measurements which were conducted once per 
hour for each sample for 6 hours. In studies II and III, the aggregation measurement was 
automatized and DLS Wyatt DynaPro Plate Reader II (Wyatt Technology, California, USA) 
was used in the measurements. In this method, samples were coated with paraffin oil to 
prevent sample evaporation and the data were collected with Dynamics V7 (Wyatt 
Technology, California, USA). The temperature was set to 37°C and each sample were 
measured every 15 to 30 minutes for 6 to 8 hours. The automatization of the method 
increased the sample size that was possible to measure per day by about 30-fold together 
with D2O isolation (instead of KBr). The radius of native LDL particles starts to grow from 
native LDL with its 14 nm radius to heavily aggregated particles having a radius over 1000 
nm. The accuracy of the dynamic light scattering measurement is limited to approximately 
3000 nm because of the wavelength of the laser and thus the maximum size measured was 
limited to that size. From the raw data, time (h) – aggregate size (nm) curves are fitted using 
R-programme or GraphPad Prism and aggregate size at timepoint 2h or inflection point is 
determined. 
4.2.4 Lipid extraction and mass spectrometry 
Three different lipid mass spectrometers (MS)s were used to analyse the lipid composition 
of the samples. Lipidomics of LDL from the SYSDIET-study, the Ethnicity-study, the 
myriocin mice and the in vivo modified human LDL samples were analysed using Agilent 
6490 or 6410 Triple Quad LC/MS with iFunnel technology (Agilent Technologies, Santa 
Clara, USA) in the Helsinki University Lipidomics Unit. Total lipids were extracted into 
chloroform-methanol (1:2, v/v) from blood plasma isolated LDL samples using Folch 
protocol (176). Prior to the analysis, lipid extracts were evaporated under a stream of 
nitrogen and dissolved in chloroform/methanol (1:2, v/v) and spiked with a mixture of 
quantitative internal standards. This standard included a separate standard for each analysed 
lipid class with a known concentration. A solution of 1% (v/v) NH4OH or NH3 was added 
to the samples just prior to the analysis to support ionization and prevent sodium adduct 
formation. The sample solutions were injected immediately via a syringe pump into the 
53 
 
electrospray ionization (ESI) source of a triple quadrupole mass spectrometer at a flow rate 
of 10 µl/min. Lipids with a choline head group (PC, LPC, SM) were detected by using an 
MS/MS precursor ion scan (precursors of m/z 184) and CE using MS/MS precursor scan of 
m/z 369. Triacylglycerols (TAG)s were analysed using an MS+ scan as (M+NH4)+ ions 
(177). The mass spectra data was analysed with Mass Hunter Workstation qualitative 
analysis software (Agilent Technologies, Inc.) and lipids were quantified using the internal 
standards and Lipid Mass Spectrum Analysis (LIMSA) software (188). The acyl chain 
assemblies were studied by recording their acyl chain either by recording negative ion mode 
product ion scans of the anion fragments for all common fatty acids (178). In this scan, 
formate adducts were used to serve as mother ions for choline lipids, which do not ionize in 
the negative mode as such, and the subsequent anionic fragments of the acyl chains were 
measured. In the other method, the acyl chain assemblies were studied by recording acyl 
chain specific MS/MS fragments (179). In this method, positive ion mode neutral loss scans 
of different acyl chains were detected for TAG species and negative ion mode precursor 
scans of the acyl fragments for PC species, of which formate adducts were used as mother 
ions. 
Lipidomics for Corogene-study and Health 2000 Health Examination Survey were analysed 
using a 5500 QTRAP (SCIEX, Framingham, MA) mass spectrometer equipped with 
Eksigent 100-XL UHPLC system at Zora Biosciences (Espoo, Finland). Internal standard 
was added to the samples as well as protein precipitation solvent and lipids were extracted 
with acetate/isopropanol (2:8, v/v). Immediately prior to the analysis, 10 mM NH4CH3CO2 
in acetonitrile/2-propanol (4:3), v/v) with 0.1% formic acid was added in sample solution 
(180). 
Lipidomics in the overfed study were analysed by using the UHPLC-QTOFMS system, 
Agilent Technologies (Santa Clara, CA, USA) combining 1290 Infinity system and 6545 
quadrupole time of flight mass spectrometer (QTOFMS), interfaced with a dual jet stream 
electrospray (dual ESI) ion source at Örebro University, Sweden where lipids were extracted 
by using a slightly modified Folch method (189). 
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4.2.5 LDL binding to proteoglycans 
Human aortas were obtained from autopsy within 24 hours of accidental death from the 
Department of Forensic Medicine, University of Helsinki (permission from the National 
Authority for Medicolegal Affairs; no 923/32/200/05). Proteoglycans were extracted from 
the intima media layer of the aortas as described before (181,182). 96-well plates were 
coated with intimal proteoglycans, blocked with 1 % BSA and 1µl of plasma was added and 
incubated at 37°C for 1 hour. Control wells were blocked with BSA, but not coated with 
proteoglycans. After washing unbound LDL and other lipoproteins from plates, the amount 
of total cholesterol was measured with the Amplex Red cholesterol assay kit (Molecular 
probes® by life technologies, Oregon, USA) by following the manufacturer’s instructions. 
4.2.6 Circular dichroism 
Circular dichroism (CD) spectroscopy was performed as described before when analysing 
the apoB-100 conformation (83,183). LDL samples for CD analyses were diluted to 1 mg/ml 
in MES buffer, pH 5.5. The LDL samples were treated with SMase for 30 minutes and 10 
mM EDTA was used to stop lipolysis. Control samples were treated identically, but without 
lipolysis. Lipolyzed and control LDL particles were diluted to 50 µg/ml for CD analysis and 
placed in 0.1 cm quartz cuvettes. CD spectra were registered with JASCO J-715 
spectropolarimeter (Japan Spectroscopic Co.; Tokyo, Japan) in the region of 190-250 nm 
with step size 0.5 nm, scan speed of 50 nm/min, band width of 1 nm, and 1 s response at 37 
± 1 °C. Five spectra were obtained for each sample and average spectra were calculated from 
these after the blank measurements were subtracted.  
CD signals at 222 nm, were used in the kinetic analysis of apolipoprotein folding. Molar 
ellipticity ([Θ]) at 222nm was calculated from the equation: [Θ] = (MRW)* Θ/10lc, where Θ 
is a measured ellipticity in degrees, l is the cuvette path length (0.1 cm), c is the protein 
concentration (g/ml), and the mean residue weight (MRW) is obtained from the molecular 
weight and the number of amino acids. The α-helix contents were calculated from the 
equation using [Θ] at 222 nm: percent α-helix = [(-[Θ] 222+ 3,000)/(36,000 + 3,000)] * 100 
(190,191). 
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4.2.7 Cell culture 
Human primary macrophages 
Human white blood cell fractions (buffy coats) were obtained from heathy volunteers 
(Finnish Red Cross Blood Service, Helsinki, Finland, (permission; no 1/2015 and 11/2016). 
Monocytes were plated to 8-well or 24-well plates (1.5 million cells per well), and the cells 
were allowed to attach for 1 h, washed three times with phosphate buffered saline (PBS) and 
serum free macrophage medium (GIBCO, Theromo Fisher Scientific, Co Dublin, Ireland) 
with 50 ng/ml recombinant human macrophage colony-stimulating factor (M-CSF). The 
medium was changed every other day for one week, during which monocytes had 
differentiated into macrophages (93,184). Native LDL samples and LDL samples were 
pretreated with SMase for 4 or 24 hours and lipolysis was stopped with 10 mM EDTA; 
EDTA was added in equal amounts to the native LDL samples. Native LDL, SMase-
aggregated LDL or acetylated LDL were added to macrophages in 24 well plates in serum-
free RPMI 1640 media (Lonza, Walkersville, USA) containing 2 mM L-glutamine, 100 
units/ml penicillin and 100 µg/ml streptomycin. After an overnight incubation, the media 
was collected for matrix metalloprotease (MMP)-1, -2, -3, -7, -9, -10, -12, and -13 analyses. 
The concentrations of MMPs in culture media were measured using Human MMP Luminex 
Performance magnetic panel (R&D systems, Minneapolis, USA) according to the 
manufacturer’s instructions. Cells were washed with PBS and intracellular lipids were 
extracted with hexane/isopropanol (3:2, v/v), 30 µl of lipid extract was pipetted into 96-
wells, evaporated, and total cholesterol was determined with the cholesterol Amplex Red 
cholesterol kit (Molecular probes® by life technologies, Oregon, USA) according to the 
manufacturer’s instructions.  
To visualize the cholesterol accumulation in macrophage foam cells onto 13 mm glass 
coverslips in 8-well plates were washed after the incubation and fixed with 3.7 % formalin 
for 3 minutes at room temperature. Neutral lipids were stained with Oil Red O and 
counterstained with hematoxylin. Aquamount (BDH Laboratory Supplies, Poole, England) 
was used to mount coverslips on glass microscope slides and photographed (185). 
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T cells 
48-5 T cell hybridomas from human apoB-100 transgenic mice were originally immunized 
against human oxLDL, but surprisingly responded only to native LDL, not to oxLDL (186). 
Irradiated (25 Gy) splenocytes were used as antigen presenting cells. C57BL/6J mice 
(Jackson, Bar Harbor, Maine) were sacrificed and spleens were harvested and meshed 
through a 100 µm cell strainer followed by osmotic lysis of red blood cells (EL buffer, 
Qiagen, Hilden, Germany). These mice were housed and treated in Karolinska Institutet, 
Stockholm, Sweden and study protocols were approved by the Stockholm North Committee 
for Experimental Animal Ethics. Splenocytes were co-cultured with 48-5 T-cell hybridomas 
and incubated with 10 µg/ml of native LDL or SMase aggregated LDL, or Concanavalin A 
as a positive control. The cells were incubated in 96-well plates with 200 µl serum-free RPMI 
1640 medium containing ITS Premix (Corning, Bedford, Massachusetts), 0.1% bovine 
serum albumin, nonessential amino acids, L-glutamine, 1 mM sodium pyruvate, and 50 µM 
β-ME for 24 hours at 37°C in a humid 5% CO2 atmosphere. T cell activation was measured 
via the IL-2 concentration in the supernatant using ELISA (Mabtech, Nacka Strand, Sweden) 
according to the manufacturer’s protocol.  
4.2.8 Mouse models 
Large ´empty´ vesicle-treated mice 
Human APOB100 transgenic, Ldlr-/- -mice were housed in the University of Gothenburg, 
Sweden. Mice were on chow diet and food and water were served ad libitum. Large ´empty´ 
vesicles (LEVs, also known as unilamellar vesicles), having diameter of 100 nm were 
injected intravenously into mice once, with PBS being administered to the control mice. 
Mice were 13-19 weeks old and LEVs were dosed at 1000 mg PC/kg (body weight). One 
hour after injection of LEVs (n=16) or PBS (n=16), blood was collected, and plasma was 
isolated. LDL and VLDL fraction were isolated by KBr ultracentrifugation, but because 
LEVs can appear in LDL density range, VLDL-LDL samples were further purified. The 
LDL fraction was loaded into a Superose 6 HR column (size-exclusion FPLC), and eluted 
with 150mM NaCl, 1mM EDTA, pH 7.4. The first peaks for LEVs and VLDL were 
discarded, the subsequent LDL fractions were collected and pooled in pairs and re-loaded 
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onto the Superose 6 HR column, eluted with 150 mM NaCl, 1 mM EDTA pH 7.4; after this 
procedure, only LDL was detected. The animal procedures were approved by the Animal 
Ethical Committee at the Gothenburg University. 
Myriocin treated mice 
Ldlr-/-, Apob100/100-mice were housed in the National Laboratory Animal Center of the 
University of Eastern Finland. All mice were male and on chow diet until treatment with 
myriocin (n=11), or PBS (n=11) at the age of 14-22 weeks, when the animals were fed a 
high-fat atherogenic diet (21% milk fat, 0.2% cholesterol; Harlan Teklad; TD88137; also 
called the ‘Western’ diet), food and water were available ad libitum. Mice were injected 
intraperitoneally three times every week (Monday, Wednesday, Friday) for 10 weeks with 
myriocin (0.3mg/kg, Biomol Research Laboratories Inc.) or PBS. After the 10-week 
treatment, mice were fasted for 4h and terminal anaesthetised with isoflurane inhalation 
(Vetflurane 1000 mg/g, Virbab animal health), and blood was collected with heart puncture 
under deep anaesthesia. The aortas were collected and fixed with 4% paraformaldehyde 
(PFA) in PBS. These animal procedures were approved by the National Animal Experiment 
Board of Finland and carried out in accordance with the guidelines of The Finnish Act on 
Animal Experimentation. 
Soat2-/- mice 
Human APOB100 transgenic, Ldlr-/-, Soat2-/- (n=5), and human APOB100 transgenic, Ldlr-/-, 
Soat+/+ mice (n=3) were housed in Wake Forest University. These mice are deficient in sterol 
O-acyltransferase 2 (SOAT2), an enzyme esterifying cholesterol; the animals are 
characterized by the enrichment of polyunsaturated CEs and TGs (187). Mice were fed for 
8 months with a diet rich in cis-monounsaturated fat as described before (187). Plasma was 
collected and LDL particles were isolated with KBr ultracentrifugation. These animal 
procedures were approved by the Institutional Animal Care and Use Committee at Wake 
Forest University Health Sciences.  
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4.2.9 Statistical methods  
The results are presented for normally distributed data as average ± SD (or SEM) or if data 
was not normally distributed as median and interquartile ranges. For normally distributed 
data, the statistical significance between groups was determined using Student´s t-test when 
comparing two groups and paired t-test when differences were tested within individuals of 
paired samples. One-way ANOVA was used in the comparison of more than two groups 
followed by Dunn´s post hoc tests. Mann-Whitney U or Kruskal-Wallis test was used to 
compare non-normally distributed data. A two-tailed Spearman correlation coefficient was 
used to analyse correlations between variables. If required, the test was followed by a post-
hoc test. P-values ≤ 0.05 were considered significant. All statistical analyses were performed 
using IBM SPSS Software version 22.0, 23.0, 24.0 or 25.0 (IBM, North Castle, NY) or 
GraphPad Prism Software version 8.0.1 (La Jolla, CA). 
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5 RESULTS  
5.1 LDL AGGREGATION IN ATHEROGENESIS 
LDL aggregation in arterial intima is one of the crucial first steps in atherogenesis. 
Aggregated LDL particles cannot diffuse back to the circulation, they bind to intimal 
proteoglycans, resulting in LDL retention in the intima, and therefore they are prone to 
undergo further modifications (192). Macrophages phagocytose aggregated LDL and form 
foam cells, leading to plaque formation (89). In addition to other inflammatory cells, CD4+ 
T-cells, also called T helper cells, are present in atherosclerotic lesions and they have been 
demonstrated to be pro-atherogenic (97).  
In addition to these previously known atherogenic properties of LDL aggregation, this thesis 
revealed that cultured human primary monocyte-derived macrophages, exposed to SMase-
induced aggregated LDL led to massive foam cell formation and that these foam cells started 
to secrete increased amounts of MMP7 into the culture media (Study I, Figure 6A-C). In 
previous studies, MMP7 has been associated with plaque instability and adverse events in 
patients with carotid atherosclerosis (193). SMase-aggregated LDL also activated CD4+ T 
cells in an aggregate size dependent manner (Study I, Figure 6D). T cell activation was 
measured via IL-2 secretion and this was found to be blunted in the presence of oxLDL as 
shown before (186). CD4+ T cells are pro-atherogenic; they increase the level of 
inflammation and promote the development of a pathological lesion (194).   
5.2 MEASUREMENT OF LDL AGGREGATION 
SUSCEPTIBILITY 
One aspect of this thesis was the development of a method to measure LDL aggregation 
susceptibility from plasma or serum samples. In the devised method, LDL was isolated from 
blood by sequential ultracentrifugation, then LDL aggregation was induced by incubation 
with hrSMase with the LDL particle size being followed with dynamic light scattering. The 
LDL aggregate size at timepoint 2-h clearly correlated with the inflection point and could 
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pinpoint individuals with aggregation prone LDL (Study I, Supplementary Figure 3A-C, 
Study II, Figure 1B-C). 
It was found that LDL aggregation varied between individuals, and furthermore each of 
tested LDL aggregation methods i.e. oxidation, proteolysis, and lipolysis by PLA2, bcSMase 
and hrSMase all revealed a similar separation between individuals. Of these methods, 
hrSMase resulted in the formation of the largest sized aggregates, and the greatest 
differences between individuals and therefore, it was chosen for systematic analysis of the 
samples. Importantly, LDL aggregation susceptibility did not correlate with common risk 
factors for ASCVD, such as age, smoking, gender, LDL-C, apoB-100, Lp(a) or high 
sensitivity C-reactive protein (hsCRP). (Study I, Supplementary Tables 1 and 2). 
The LDL concentration at the beginning of the incubation with hrSMase was found to 
influence the LDL aggregation, i.e. the higher the concentration, the faster the aggregation. 
A concentration of 0.2 mg/ml was chosen for the standard protocol, because LDL 
aggregation changed only relatively marginally if the LDL concentration was increased or 
decreased from the 0.2 mg/ml (Study I, Supplementary Figure 2A). 
The inter – assay variance was found to be small in an experiment where the plasma from a 
single individual was divided into 26 aliquots and separately isolated and analyzed. Plasma 
freezing to -80 °C once, did not affect LDL aggregation and freezing – thawing up to five 
times had only a small effect with this difference only being detectable after 4-h incubation. 
Intra-individual day-to-day variance was found to be minor (Study I, Supplementary Figure 
2B-D). 
5.3 LDL LIPID COMPOSITION ALTERS THE APOB-
100 CONFORMATION AND THEREBY CHANGES 
THE LDL AGGREGATION SUSCEPTIBILITY 
To examine the associations between LDL susceptibility and LDL lipid composition, both 
were analysed from the same samples from 100 healthy individuals (Health 2000). The LDL 
lipid composition was determined using quantitative lipid mass spectrometry based 
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lipidomics. It was discovered that LDL aggregation susceptibility was positively associated 
with several SM and Cer species and negatively associated with several PC species (Study 
I, Figure 2B). With respect to the core lipids, there were no clear associations with LDL 
aggregation susceptibility. However, 48-52 carbon TAGs correlated negatively with the 
LDL aggregation susceptibility in Health 2000 study (Study I, Figure 3A). Furthermore, the 
lipid-LDL aggregation susceptibility association was consistently found in all of the 
following cohorts examined in this thesis i.e. Corogene (Study I, Figure 2B,3B), SYSDIET 
(Study I, Figure 4C, changes), Equator (Study I, Figure 4F, changes), Ethnicity (Study II, 
Figure 2A) and Hypercaloric (Study III, Supplemental figure 4A,B) studies. 
The causality of surface lipid composition to LDL aggregation susceptibility was studied in 
vivo and in vitro. Isolated LDL particles were directly enriched in vitro with SM, PC or LPC 
and LDL lipid composition, LDL aggregation susceptibility and apoB-100 conformation 
were evaluated from the original LDL samples and the lipid-enriched LDL samples. The 
changes in relative proportions of SM, PC and LPC were in a similar range as had been 
observed between individuals (Study I, Supplementary Figure 4A). The LDL particles 
enriched in SM became more prone to aggregation, whereas particles enriched in PC or LPC 
became more resistant against aggregation (Study I, Supplementary Figure 4B). It had been 
shown earlier that SMase treatment of LDL particles induced changes of apoB-100 
conformation by decreasing the α-helical structures of apoB-100 (83). One mechanistic 
explanation for this finding is that the changes in the surface lipid composition altered apoB-
100 conformation already in non-lipolyzed LDL particles. Furthermore, SM enrichment 
enhanced SMase-induced conformational changes of apoB-100 (Study I, Supplementary 
Figure 4C, D). 
For the in vivo experiments, we chose mouse models that had been previously shown to 
change LDL lipid composition and reduce atherosclerosis without affecting the plasma LDL 
concentration (195-197). The purpose of the first mouse model was to increase the amount 
of LDL-PC. Human APOB100 transgenic/Ldlr-/-  mice were intravenously injected with a 
single dose of large empty vesicles (n=16), composed of PC 16:0/18:1; the  control group of 
APOB100 transgenic/Ldlr-/- littermates, received equivalent dose of PBS (n=16). Both 
SM/PC and UC/CE were decreased in LEV treated mice group compared to controls, the 
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SM/PC ratio was three-fold lower and the UC/CE ratio was two-fold lower. LEV treatment 
led to the formation of almost completely aggregation-resistant LDL i.e. even after overnight 
incubation with hrSMase, the LDL aggregate size was found to be small (Study I, Figure 
5A). 
The purpose of second mouse model was to reduce LDL-SM by suppressing SM 
biosynthesis. Ldlr-/-/Apob100/100 mice were injected intraperitoneally with either myriocin or 
PBS three times per week for ten weeks, simultaneously while consuming a high fat diet 
(n=22). Myriocin is an inhibitor of serine-palmitoyl transferase, the first step and the rate-
limiting enzyme in the biosynthesis of SM. Plasma levels of cholesterol and TGs increased 
in both groups equally due to high fat diet, but the SM/PC ratio was halved in the myriocin 
treated mice group. (Study I, Supplementary Figure 8) With this model, we also could 
demonstrate that atherosclerosis was decreased in the myriocin treated group (Study I, 
Figure 5C), as shown previously in a different atherogenic mouse model (196). Finally, LDL 
aggregation was decreased in myriocin treated mice group when compared to control mice 
(Study I, Figure 5B). 
In the third mouse model, it was investigated if modification of core lipids would exert an 
effect on the LDL aggregation susceptibility. For this purpose, SOAT2 deficient mice were 
used; these mice lack the enzyme known alternatively as sterol-O-acyltransferase 2, or 
cholesterol acyl-CoA acyltransferase-2 (ACAT2). SOAT2 esterifies cholesterol 
predominantly in the liver and small intestine (198,199), and previously inhibition of SOAT2 
has been shown to reduce atherosclerosis (200). Soat2-/- mice are characterized by the 
enrichment of polyunsaturated CE and TAG in LDL particles in their blood as compared to 
Soat2+/+  littermates (187). In this study, LDL was isolated from blood samples of APOB100 
transgenic/Ldlr-/-/Soat-/- mice (n=5) and APOB100 transgenic/Ldlr-/-/ Soat2+/+ littermates 
(n=3). The LDL particles in the blood of SOAT2 deficient mice was found to be extremely 
resistant to aggregation (Study I, Figure 5D). 
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5.4 AGGREGATION PRONE LDL PREDICTS FUTURE 
ASCVD DEATHS INDEPENDENTLY OF 
CONVENTIONAL RISK FACTORS  
Plasma LDL-C is an independent, causal risk factor for ASCVD and LDL aggregation is 
one of the first steps in atherogenesis (4,201). However, conventional risk factors, including 
plasma LDL-C do not identify all patients at risk for MI.  The amount of patients with zero 
conventional risk factors who nonetheless suffer an MI varies from 8 to 41%; this value, is 
higher in males, and increases with age (202). The majority of patients that experience out-
of-hospital sudden cardiac arrest have no symptoms prior the event or their risk have been 
classified as low risk if disease is previously identified (203,204). Clearly new risk factors 
are needed to identify and then to treat these patients, who carry this insidious and 
unrecognised risk for MI. Here, it was studied if LDL aggregation susceptibility would 
associate with CADs and/or CAD death independently of conventional risk factors. 
In these experiments, samples were analyzed from a nested case-control study (31), which 
was originated from the prospective Finnish Corogene study (168). Patients were assigned 
for coronary angiogram and patients with at least 50% stenosis in their coronary arteries 
were chosen for this study. Exclusion criteria for the substudy included diabetes, heart 
transplantation, previous blood transfusion and low haemoglobin and female sex. Blood 
samples were taken and then patients were followed for an average of 2.5 years. Those 
patients that suffered a coronary death within the follow-up period were designated as the 
case group (CAD Death group, n=24). Controls were chosen from the group of patients that 
experienced no cardiovascular events during the follow-up time (Stable CAD group, n=24) 
by pairwise matching them with cases based on conventional risk factors, coronary stenosis 
index and statin use. Inter-individual variation in LDL aggregation susceptibility was 
observed as described earlier among healthy subjects. Importantly, LDL aggregates were 
significantly larger at the 2 h time point in the CAD Death group (median 1500 nm) when 
compared to the Stable CAD group (median 940 nm, p<0.05). Both groups, with diagnosed 
CAD, were observed to have very significantly larger LDL aggregate sizes compared to 
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LDL aggregates from healthy individuals from Health 2000 study participants (median 200 
nm, p<0.001 for both) (Study I, Figure 1D). LDL aggregation susceptibility, measured as a 
particle size at 2 h, did not correlate with plasma LDL-C, apoB-100, HDL-C, total 
cholesterol, Lp(a) or high sensitivity hsCRP, nor with age, BMI, statin use, smoking or LDL 
particle size. (Study I, Supplementary Table 2) In Corogene study and in Health 2000, a 
negative correlation with TGs was observed with the LDL aggregation susceptibility (Study 
I, Supplementary Tables 1 and 2). 
5.5 LDL OF SOUTH ASIANS IS MORE PRONE TO 
AGGREGATION COMPARED TO WHITE 
CAUCASIANS 
South Asians have a higher risk to develop ASCVD in comparison to other ethnic groups 
(40,41). To some extent, this is due to their higher prevalence of traditional ASCVD risk 
factors, but it is not fully explained by these factors (42-44). It was examined if LDL 
aggregation is higher in healthy young South Asians (n=12, age 27.5 ± 3.2 years) compared 
to white Caucasian males (n=12, age 25.6 ± 3.2 years). All the study subjects lived and had 
been born in the Netherlands, and the groups were matched according to their age, BMI, 
blood pressure, plasma TG, LDL-C, HDL-C, insulin and glucose. I observed, similarly to 
others (205,206), that South Asians have a higher body fat % than white Caucasians (19 % 
vs. 15 %, p=0.015) with a similar BMI. (Study II, Table 1) The LDL aggregation 
susceptibility was observed to be higher within South Asians compared to white Caucasians 
(aggregate size at 2h; 620 ± 320 nm vs 350 ± 290 nm, p = 0.011). (Study II, Figure 1D). The 
LDL aggregation susceptibility positively correlated with body fat % (Study II, Figure 4A), 
and both LDL aggregation susceptibility and body fat % correlated positively with SM 24:0 
and TAG 56:8 and negatively with CE 18:1 in South Asians (Study II, Figure 2 and 4). 
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5.6 LDL AGGREGATION SUSCEPTIBILITY IS 
MODIFIABLE WITH DIET 
A Healthy Nordic diet has been shown to be beneficial for cardiovascular health (161,162). 
Here, the effect of diet for LDL aggregation was studied in three different intervention. In 
SYSDIET –study (167,207), where participants were randomized to eat Healthy Nordic diet 
or control diet. All study subjects were overweight and had in addition two features of the 
metabolic syndrome, but without type 2 diabetes.  In the healthy Nordic diet group, the 
participants were instructed to consume whole grain products, an abundance of fruits and 
vegetables and fatty fish among other recommendations. In the control group, the diet was 
designed based on the mean consumption of nutrients in the Nordic countries and for 
example, the amount of fibres, and fruits and vegetables was limited for this reason. Key 
foods were provided for both groups. The diets were isocaloric and lasted for 18 to 24 weeks. 
Four-day food diaries were collected at the baseline and at the end point. The clinical 
characteristics and the macro- and micro-nutrient amounts of the study subjects are presented 
in Study I, Supplementary Table 3 and Supplementary Figure 5A.  
It was studied here if LDL aggregation susceptibility would change from samples taken at 
the baseline and at the end of the intervention in both groups. It was found that the level of 
LDL aggregation decreased in two third of the cases in individuals in the Healthy Nordic 
diet group, but increased in one third of the cases (Study I, Figure 4A). In the control group, 
only small changes were observed in LDL aggregation susceptibility (Study I, Figure 4B). 
In the Healthy Nordic diet group, changes in the LDL aggregation susceptibility correlated 
positively with LDL-SMs, and negatively with LDL-PCs (Study I, Figure 4C). It was 
analysed further if these changes in LDL lipids and LDL aggregation could be explained by 
changes in diet in the Healthy Nordic diet group. The multivariate model identified two 
factors that best explained the changes in LDL aggregation susceptibility, changes in dietary 
vitamin E and changes in dietary sucrose (Study I, Table 4). The increase in dietary vitamin 
E was associated with a decrease in LDL aggregation susceptibility, whereas an increase in 
dietary sucrose was associated with increased LDL aggregation susceptibility. Dietary 
vitamin E was a marker of the intake of polyunsaturated fatty acid rich vegetable oils, not a 
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supplement. Dietary vitamin E and dietary polyunsaturated fatty acids were associated 
positively with LDL-PC and negatively with LDL-SM, and were considered to be strongest 
beneficial factors modifying both the LDL lipid composition and LDL aggregation 
susceptibility (Study I). 
Next, it was studied in an extreme study setting if over-consumption of saturated fats, 
unsaturated fats of simple sugars would exert any effect on LDL lipids and LDL aggregation 
susceptibility. All the study subjects were overweight also in this study, and randomized to 
consume 1000 extra calories per day in addition to their regular diets for three weeks. The 
clinical characteristics of the study subject were described in Study III, Table 2. The extra 
calories came predominantly from saturated fats (SAT group), unsaturated fats (UNSAT 
group) or simple sugars (CARB group). The extra food was provided for each group, and 
they consisted of blue cheese, butter and coconut oil in SAT group, olive oil, pesto, pecan 
nuts and a small amount of butter in the UNSAT group, and candy, sugar-sweetened 
beverage and orange juice in CARB group (Study III, Table 1). Fasted plasma samples were 
collected at the baseline and after the intervention. The compliance of the diets was verified 
by analysing VLDL-TGs; in the CARB group, the amounts of unsaturated fatty acid-TAGs 
were increased due to de novo lipogenesis, producing mainly palmitic acid (16:0). In the 
SAT group, saturated-TAGs were increased and unsaturated-TAGs decreased, while in 
UNSAT group unsaturated TAGs increased (Study III, Figure 1). 
It was studied if any of the diets had any effect on the atherogenic properties of LDL i.e. 
LDL aggregation susceptibility, LDL lipidomics, LDL binding to human proteoglycans or 
LDL oxidation. In the CARB group, it was found that the amount of saturated-TAGs in LDL 
particles was increased and that of unsaturated-TAGs had decreased, in line with VLDL lipid 
analyses. In addition, there were small, inconsistent changes in LDL-PC species (Study III, 
Figure 4C). The CARB diet had no effect on any of the measured functional properties of 
LDL, LDL aggregation (Study III, Figure 5C), LDL binding to proteoglycans (Study III, 
Figure 2B, C) or LDL oxidation (Study III, Figure 3B, C). In the UNSAT group, many LDL-
PC species were slightly, but consistently decreased, total TAGs were decreased, and CEs 
increased (Study II, Figure 4A). The level of LDL binding to human proteoglycans was 
significantly decreased in the UNSAT group but the diet had no effect on other functional 
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properties of LDL particles (Study III, Figures 2B, C, 3B, C, 5C). In the SAT group, most 
substantial changes in LDL lipids were found, most importantly many LDL-SMs were 
increased. In addition, the amounts of saturated fatty acids containing PCs and TAGs were 
increased and unsaturated fatty acids containing PCs and TAGs were decreased (Study III, 
Figure 4B). Most importantly, the LDL aggregation susceptibility was increased in the SAT 
group (Study III, Figure 5C), and this increase associated positively with LDL-SM species 
and negatively with LDL-PC species (Study III, Figure 5E).  
 
5.7 LDL AGGREGATION SUSCEPTIBILITY IS 
DECREASED WITH PCSK9 MONOCLONAL 
ANTIBODY TREATMENT  
PCSK9 inhibition with mAbs dramatically lowered the amount of LDL-C and this is 
recommended for patients at a high risk for ASCVD events. The LDL aggregation 
susceptibility did not correlate with the LDL-C concentration in any of these studies (I, II, 
III), however we have found that PCSK9 mAb treatment altered both the plasma and 
lipoprotein PL compositions (208). 
The samples were obtained from a randomized, double-blind, phase 2 study of fully human 
immunoglobulin G1 (IgG1) mAb against PCSK9 (RG7652), called the EQUATOR study. 
RG7652 (n = 25) or placebo (n = 15) were once injected subcutaneously to the patients, and 
blood samples were taken before and 29 days after the treatment. The LDL aggregation 
susceptibility was decreased in two out of every three RG7652-dosed patients, in the placebo 
group, LDL aggregation slightly decreased in one out of every three samples (Study I, Figure 
4D-E). Changes in LDL aggregation susceptibility were significantly different (p = 0.035) 
between the groups. In the RG7652-dosed group, changes in LDL aggregation susceptibility 
correlated negatively with total PC and several polyunsaturated PC species, and positively 
correlated with SM 18:1/16:1 and SM 18:1/22:0 (Study I, Figure 4F).  
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6 DISCUSSION 
 
Despite the administration of effective LDL-C lowering therapies, the risk for ASCVD 
remains and as many as every second person dying from a CAD event does not experience 
any symptoms prior to the event (12). Therefore, much research still needs to be done in 
order to detect and treat these patients who carry some unrecognized risk(s) for CAD. This 
study focused on examining LDL aggregation susceptibility from a mechanistic viewpoint 
and as a potential predictive risk-factor for CAD death.  
Even though the role of LDL aggregation in atherogenesis is well established (36,82,84-
90,209), it has not been proposed before as a measurable risk factor for ASCVD. A high 
LDL concentration is itself a risk factor for ASCVD and LDL is more likely to aggregate 
when present at higher concentrations. Therefore lowering the LDL concentration is one 
way to reduce the tendency of LDL aggregation in the artery wall. This thesis shows that 
there is extensive, inter-individual variation in LDL aggregation susceptibility (Study I), and 
those individuals who have the aggregation prone LDLs might benefit most from intensive 
LDL-C lowering therapies. First and foremost, this thesis showed that LDL aggregation 
susceptibility, measured from plasma samples, predicted future CAD deaths in a group of 
patients with established coronary atherosclerosis, independently of conventional CAD risk 
factors including plasma LDL-C concentration, smoking, and hypertension (Study I). 
(Figure 8) Because of the relatively small number of examined patients, the present results 
will need to be verified with a larger cohort, and also in geographically different populations, 
and different patient groups. The preliminary data from a study, where patients with severe 
PAD undergoing lower revascularization, indicates that LDL aggregation is increased 
among PAD patients (n=239) in comparison to sex, age and ethnicity matched controls 
(n=20, p<0.001) (210). In addition, pre-operative LDL aggregation predicted post-operative 
major cardiovascular events (p=0.02) when corrected for conventional risk-factors (210). 
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Figure 8. LDL aggregation. Sphingomyelin-rich LDL particles isolated from plasma 
samples are prone to aggregate and the presence of aggregation-prone LDL particles predicts 
future CAD deaths independently of conventional CAD risk factors. LDL particles that are 
more resistant to aggregation are enriched with phosphatidylcholines. SMase, 
Sphingomyelinase, CAD, coronary artery disease. Figure created with BioRender.com. 
 
In order to mechanistically explain inter-individual variation in LDL aggregation 
susceptibility, a detailed lipidomic analysis was performed in seven different cohorts. The 
aggregation prone LDL particles consistently associated with a higher relative proportion of 
SMs and aggregation resistant LDL particles associated with a higher relative proportion of 
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PCs (Studies I-III). Plasma sphingolipids, which are carried in plasma in lipoprotein 
particles, have been related to increased atherosclerosis and cardiovascular deaths (31-34). 
Our results may partly explain the mechanism behind these findings. Further associations 
between plasma sphingolipids and LDL aggregation susceptibility remain to be clarified. 
Form the clinical viewpoint, it is relevant to determine whether LDL aggregation 
susceptibility can be modified. To study if this was the case, the LDL composition was 
pharmacologically and genetically modified in vivo. Increasing LDL-PC by vesicle 
treatment, decreasing LDL-SM by inhibiting SM biosynthesis and increasing 
polyunsaturated TAGs and CEs, all resulted in a reduced LDL aggregation susceptibility 
(Study I). Similarly, direct in vitro enrichment of isolated LDL particles with SM increased 
LDL aggregation and PC or LPC enrichment decreased LDL aggregation. These in vivo and 
in vitro interventions verified the causal role of LDL lipids in the LDL aggregation 
susceptibility but were not relevant clinical approaches. Therefore, it was further studied if 
diet, genetic background or medication would be capable of affecting an individual’s LDL 
aggregation susceptibility (Studies I-III). 
First, the Healthy Nordic diet study showed that vegetable oil consumption, measured as 
dietary vitamin E intake, was associated with reduced LDL aggregation, while the 
consumption of sugars best explained the elevated LDL aggregation (Study I). In an extreme 
study setting, it was further investigated if overconsumption of saturated fats, unsaturated 
fats, or simple sugars would alter the LDL lipid composition and the LDL aggregation 
tendency. It was observed that overconsumption of saturated fats did result in increased 
levels of LDL-SM and increased LDL aggregation, whereas unsaturated fats or sugars did 
not have any effect on LDL aggregation (Study III). The increase in the level of  LDL-SM 
is likely due the fact that a saturated fat diet is rich in palmitate, a precursor of palmitoyl-
CoA, a rate-limiting substrate of SM biosynthesis (211,212). Dietary saturated fats are also 
known to increase plasma LDL-C levels, and CAD risk (4,128). Our results here support the 
harmfulness of dietary saturated fats for cardiovascular health. 
Overconsumption of unsaturated fats decreased both the plasma oxLDL concentration and 
LDL binding to human aortic proteoglycans, the other proatherogenic characteristics of LDL 
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(Study III). Vegetable oil supplementation (rich in linoleic or oleic acid) has been shown 
also to reduce LDL binding to proteoglycans by our research group (213) and others (214). 
Dietary unsaturated fat, despite not affecting LDL aggregation susceptibility ((Study III) and 
(213)), does have other beneficial effects with regard to the LDL quality by reducing oxLDL 
and LDL binding to proteoglycans. However, the most beneficial effect on plasma lipids has 
been obtained when replacing dietary saturated fats with cis-PUFA (predominantly linoleic 
acid and α-linolenic acid)  (128). Accordingly, in the future it would be interesting to study 
whether this kind of intervention exerts a beneficial effect also on the LDL aggregation 
susceptibility. I have also shown that consumption of Camelina sativa oil, which is rich in 
linolenic acid (18:3), does not affect LDL SM/PC ratios or LDL aggregation (213). In the 
line with UNSAT group, LDL binding to human proteoglycans was decreased by treatment 
with Camelina sativa oil (213), but this decrease seemed to be dependent on plasma LDL-C 
levels.  
Replacing saturated fats with unsaturated fats, is only marginally effective in overweight and 
obese individuals (215,216). The participants in Healthy Nordic diet study (Study I), 
overconsumption study (Study III) and Camelina sativa oil study (213)  were all obese. 
Obesity triggers adipose tissue induced inflammation that leads to insulin resistance 
(217,218)  and insulin resistance is known to  disturb lipid metabolism, and may lead to 
elevated cholesterol synthesis and lower cholesterol absorption (219,220). The response to 
dietary changes in obese people compared to normal weight people is somewhat limited for 
these reasons (216). It is very likely that diet- induced changes in LDL aggregation 
susceptibility are also limited in obese individuals, since LDL aggregation susceptibility 
depends on LDL lipid composition. The plasma lipid composition of obese individuals is 
most likely to be affected by their excess adipose tissue. In non-human primates, it has been 
recently shown that the levels of several plasma SM species, as well as palmitoleic acid 
(C16:1) and arachidonic acid (C20:4) are higher among obese individuals (221).  In addition, 
obese humans have more palmitoleic and arachidonic acid in their adipose tissue when 
compared to their non-obese counterparts (222). 
Finally, it was studied if LDL aggregation susceptibility differed between two different 
genetic pools, South Asians and white Caucasians. LDL obtained from South Asians was 
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more prone to aggregate when compared to white Caucasians (Study II), and this may partly 
explain the higher risk of South Asians for CAD (40,41). It was observed here that LDL-
SMs were associated with a higher body fat percentage, and conversely LDL-PCs associated 
with a lower body fat percentage in the whole population studied. Furthermore, the LDL 
aggregation susceptibility was found to positively correlate with body fat percentage. This, 
together with the previous findings of the thesis, suggest that overweight/obese individuals 
may have more aggregation prone LDL. Unfortunately, in these studies it was not possible 
to detect a correlation between BMI and LDL aggregation susceptibility because of the low 
variation in the BMI values. The genetic influence on LDL aggregation susceptibility 
remains to be studied in detail. For example, the genes which regulate the expression of 
enzymes synthesising SM or PC are potential candidates as are the genes coding for 
lipoprotein and lipid receptors.  
Ingested plant stanol esters reduce LDL absorption from the intestine, resulting on average 
of a 10-15% reduction in the plasma LDL-C concentration (138,223). The effective dose is 
2-3 g per day (138) which cannot be achieved by any means other than consumption of plant 
stanol ester enriched foods.  The preliminary results suggest that the consumption of  plant 
stanol enriched rapeseed oil-based spread (3 g of plant stanol esters per day) for 6 months 
significantly (p=0.0010) was capable of decreasing the LDL aggregation susceptibility 
(224).  
LDL aggregation susceptibility does not associate with the LDL-C concentration but can be 
reduced by consumption of lipid lowering plant stanol esters. Obviously, this raises the 
question if lipid lowering medication also decreases LDL aggregation susceptibility. In this 
study, only PCSK9-mAb treatment, an extreme lipid lowering drug was studied; PCSK9-
mAb treatment successfully reduced the LDL aggregation susceptibility. As statins are the 
most common lipid lowering drugs, it would be important to study how statins affect the 
LDL aggregation susceptibility. There is also the potential to develop new treatments aimed 
at enhancing the LDL quality on an individual basis.  
From a pathological viewpoint, our results deepen the knowledge of how plasma LDL 
promotes atherogenesis in the artery wall. The higher the concentration of plasma LDL-C, 
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the greater the concentration of LDL which is present in arterial intima. At higher 
concentrations, LDL particles are more likely to aggregate and this can induce enhanced 
inflammatory responses (Study I). The observed elevated activation of T cells with SMase-
aggregated LDL is most likely due to increased phagocytosis of LDL-aggregates of antigen 
presenting cells, and this can lead to a further increase in antigen presentation to the T cells. 
 
In summary, this thesis describes a novel measurable and modifiable risk factor for CAD, 
i.e. LDL aggregation susceptibility. The future will reveal the potential of LDL aggregation 
susceptibility measurement in clinical use, for example, whether the determination of this 
parameter can help select those patients that will benefit the most from treatment with potent 
lipid lowering drugs.  
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7 CONCLUSIONS & FUTURE PERSPECTIVES 
 
The conclusions by this work are presented in Figure 9.  
 
Figure 9. Conclusions of this Thesis. The LDL aggregation susceptibility measured from 
plasma/serum samples varies among individuals. The types of LDL particles that are prone 
to aggregate are enriched in sphingomyelins (SMs) whereas LDL particles that are enriched 
in phosphatidylcholines (PCs) are resistant to aggregation. Aggregation-prone LDL is 
associated with atherosclerotic cardiovascular disease (ASCVD) and predicts ACVD deaths. 
Dietary saturated fats increase LDL aggregation, and there is some evidence to suggest that 
LDL from obese individuals aggregate more than LDL from normal-weight individuals. 
LDL aggregation susceptibility can be reduced with dietary plant stanol ester 
supplementation, by adopting a Healthy Nordic diet and by PCSK9 monoclonal antibody 
(mAb) treatment. Ethnic background has an effect on LDL aggregation susceptibility, the 
LDL obtained from Dutch men of South Asian origins tends to aggregate more compared 
than that from white Caucasian Dutch men. 
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The main finding emerging from this thesis is that LDL aggregation is not simply a 
pathological event in artery wall leading to plaque formation, but it is a measurable risk 
factor of ASCVD. This thesis demonstrates that LDL aggregation susceptibility varies 
among individuals and can be modified. Dietary supplementation of plant stanol esters 
reduces LDL aggregation (224). In obese subjects, LDL aggregation susceptibility is 
decreased by changing to eating a Healthy Nordic diet whereas it is increased by 
overconsumption of saturated fats; it is not affected by unsaturated fats or sugars. The effect 
of different diets, dietary supplements and the effect of body composition need to be clarified 
in order to verify and characterize these findings in greater detail.  
PCSK9 inhibition decreased the LDL aggregation susceptibility and may contribute to the 
preventative effect of PCSK9 mAb treatment in high risk individuals. Statin and ezetimibe 
treatment may also decrease LDL aggregation, but this will need to be examined. From a 
mechanistic point of view, the effects of the various lipid lowering drugs that have different 
mechanisms of action will provide more information about how LDL lipid composition and 
the aggregation susceptibility are altered. 
LDL aggregation susceptibility was found to be different between different ethnic groups. 
LDL from young, healthy South Asians is more prone to aggregate when compared to 
matched white Caucasians. The genetics behind individual differences in LDL aggregation 
susceptibility has not been studied, but will potentially explain the majority of these 
differences, since the modifications achievable with diet, dietary supplements or medication 
were modest when compared to inter-individual differences.  
Together with Katariina Öörni and Petri Kovanen, I have applied for a patent for the analysis 
of LDL aggregation susceptibility. The newly devised method improved and accelerated 
considerably these assays, but further developments to allow the high throughput isolation 
for LDL particles will likely be needed before this technique has widespread clinical 
applications.  
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